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Nuclear translocationThe MAPK cascades are central signaling pathways that regulate a wide variety of stimulated cellular
processes, including proliferation, differentiation, apoptosis and stress response. Therefore, dysregulation, or
improper functioning of these cascades, is involved in the induction and progression of diseases such as
cancer, diabetes, autoimmune diseases, and developmental abnormalities. Many of these physiological, and
pathological functions are mediated by MAPK-dependent transcription of various regulatory genes. In order
to induce transcription and the consequent functions, the signals transmitted via the cascades need to enter
the nucleus, where they may modulate the activity of transcription factors and chromatin remodeling
enzymes. In this review, we brieﬂy cover the composition of the MAPK cascades, as well as their physiological
and pathological functions. We describe, in more detail, many of the important nuclear activities of the MAPK
cascades, and we elaborate on the mechanisms of ERK1/2 translocation into the nucleus, including the
identiﬁcation of their nuclear translocation sequence (NTS) binding to the shuttling protein importin7.
Overall, the nuclear translocation of signaling components may emerge as an important regulatory layer in
the induction of cellular processes, and therefore, may serve as targets for therapeutic intervention in
signaling-related diseases such as cancer and diabetes. This article is part of a Special Issue entitled:
Regulation of Signaling and Cellular Fate through Modulation of Nuclear Protein Import.ation of Signaling and Cellular
Regulation, The Weizmann
343602; fax: +972 8 9344116.
r).
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The mitogen-activated protein kinase (MAPK) cascades are
evolutionary conserved, intracellular signal transduction pathways
that respond to various extracellular stimuli and control a large
number of fundamental cellular processes including growth, prolif-
eration, differentiation, motility, stress response, survival and apo-
ptosis [1–3]. Each cascade consists of three core kinases (MAP3K,
MAPKK, andMAPK), and often also additional upstream (MAP4K) and
downstream (MAPKAPK) components. Within each of the cascades,
the signal is propagated by sequential phosphorylation and activa-
tions of the sequential kinases, and they eventually lead to the
phosphorylation of target regulatory proteins by the MAPK and
MAPKAPK components. At present, four different mammalian MAPK
cascades have been identiﬁed, and named according to their MAPK
components: extracellular signal-regulated kinase 1 and 2 (ERK1/2),c-Jun N-terminal kinase (JNK), p38, and ERK5. Other kinases that
share sequence similarities with components of the MAPK cascades
have been identiﬁed as well (e.g. ERK3/4 and ERK7/8). However, the
distinct mode of activation of these kinases suggests that they are not
components of genuine MAPK cascades [4].
In order to execute their functions, the MAPKs and MAPKAPKs
phosphorylate and modulate the activities of hundreds of substrates.
The subcellular localization of these substratesmay vary depending on
the stimulation or regulated functions. Currently, such substrateswere
identiﬁed in the cytoplasm, mitochondria, Golgi, ER, and particularly
the nucleus [5–7]. The transmission of signals to the latter compart-
ment is important for the common role of the cascade, namely the
induction and regulation of de-novo gene expression [8]. For this
purpose, the signals transmitted via the different cascades need to be
transported across the nuclear envelope andmodulate the activity of a
large number of transcription factors, transcription suppressors, and
chromatin remodeling proteins, to secure the proper cellular
responses [9,10]. The transmission of signals to the nucleus is
mediatedmostly by a stimulated physical translocation of components
of the MAPK cascade into the nucleus. In this review, we will brieﬂy
describe the nature of the various cascades, and will mainly
concentrate on their nuclear roles and mechanisms of nuclear import,
which are important regulatory steps in the function of these cascades.
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The ERK1/2 cascade was the ﬁrst MAPK pathway elucidated [11],
and is considered as a prototype of these kinase cascades. This cascade
plays a central role in the signaling of a wide variety of extracellular
agents that operate via various receptors. In most cases, the
activation of such receptors is transmitted by several mechanisms
to the small GTPase Ras, which is activated mainly at the plasma
membranes. In turn, activated Ras recruits the MAP3K tier of the
cascade (mostly Raf-1 and B-Raf; Rafs) to the plasma membrane in
order to induce their activation (Fig. 1). The mechanism of B-Raf and
C-Raf activation is not fully understood yet, but is likely to include
homo- or hetero-dimerization as well as phosphorylation [12]. The
identity of the kinases that participate in the activating phosphor-
ylation of Rafs, and therefore regarded as MAP4Ks, is still under
investigation, but may include under some conditions PKC [13] and
MLK3 [14]. Thereafter, the signal is transmitted to the MAPKKs,
MEK1 and MEK2 (MEK1/2), and to a lesser extent, the alternative
spliced form MEK1b [15], by phosphorylation of two Ser residues in
their activation loop. In turn, the activated MEK1/2 transmit their
signal to ERK 1 and ERK2 (ERK1/2) [16] and the alternatively spliced
ERK1b and ERK1c [17,18] in the MAPK tier, by phosphorylating the
regulatory Thr and Tyr residues in the Thr-Glu-Tyr domain within
their activation loop [11]. Finally, the signals continue to the
MAPKAPK components (RSKs, MNKs and MSKs) and/or to many
other substrates, which are localized either in the cytoplasm, the
nucleus, or in other cellular organelles [7]. Interestingly, as initially
reported for yeast MAPKs [19], ERK1/2 can also bind directly to DNA
sequences, and act as transcriptional repressors of several cytokine-
induced genes [20].
After stimulation, the ERK1/2, as well as the MAPKAPK compo-
nents phosphorylate hundreds of substrates in many cellular
locations, and these are responsible for the induction of ERK1/2-
dependent cellular processes, including mainly proliferation and
differentiation, but also morphology determination, neuronal plas-
ticity, survival, and under some conditions stress response and
apoptosis [5]. On the other hand, when dysregulated, this cascade
plays a major role in various pathologies, inducing neurodegenera-
tive diseases [21], developmental diseases [22], diabetes [23], and
particularly notable — cancer [24,25]. The involvement of the ERK1/2
cascade in cancer has been attracting considerable attention in the
last decade, as activating mutations of signaling components up-
stream or within the cascade are responsible for more than half of all
cancers [25]. Notably, activated ERK1/2 were found also in cancers
where components of the cascade were not mutated, indicating that
the ERK1/2 cascade plays a role even in carcinogenesis induced by
apparently non-related oncogenes.
The JNK cascade was initially identiﬁed as a regulator of the
transcription factor c-Jun, and a mediator of intra- or extra-cellular
stresses, which gave it its other name, stress-activated protein kinase
(SAPKs) cascade [26]. However, like the rest of theMAPKs, it was later
shown that this cascade is also stimulated by a large number of stress-
independent stimuli and receptors including mitogens [27–29]. Upon
activation, the stress and other stimuli transmit their signals to small
GTPases such as CDC42 and Rac1, which activate the MAP3K level
kinases either directly or via MAP4Ks. Alternatively, the MAP3Ks and
MAP4Ks of the cascade can be directly activated also by stimulated
interactionwith adaptor proteins such as TRAF [30]. A large number of
MAP4Ks [31] and MAP3Ks [32] has been identiﬁed thus far, and each
of these seems to transmit the signal of the cascade by binding to
distinct scaffold proteins under distinct conditions (e.g. JIPs [33]).
Upon activation, the kinases at the MAP3K tier transmit the signals
further by phosphorylating Thr and Ser residues in the activation loop,
and thereby activating the kinases at the MAPKK level (MKK4 and
MKK7 [34]). In turn, these kinases activate the three components at
the MAPK level (JNK1-3; 46 and 54 kDa; JNKs) by direct phosphor-ylation of Tyr and Thr residues in their activation loop's Thr-Pro-Tyr
motif. Recently, MST1 [35] and MAPKAPK3 [36] were reported to be
phosphorylated by JNKs, but their function as classical MAPKAPKs is
still controversial.
Upon stimulation, the JNKs and possibly their putative MAPKAPKs,
phosphorylate a large number of substrates existing mostly in the
nucleus, but also in the cytoplasm. These phosphorylated targets
further regulate the transcription of many genes, which in turn,
mediate cellular processes such as apoptosis [37], immunological
effects [38], neuronal activity [39], insulin signaling [39], andmore [8].
The exact targets of JNKs that are involved in the regulation of all these
processes require further clariﬁcation. As would be expected from
these central roles, dysregulation of the JNK cascade leads to several
diseases. It was shown that JNKs play a role in a list of neurodegen-
erative diseases, including Alzheimer, Parkinson, amyotrophic lateral
sclerosis (ALS, [21]) and lissencephaly [40]. Other pathologies in
which JNKs are involved include diabetes [23], inﬂammation [41], and
several cancer types [42]. Therefore, better understanding of the
regulation of this cascade is likely to lead to better strategies to
combat these serious diseases.
The p38 cascade is yet another SAPK pathway that exhibits a
considerable cross-talk and shared components with the other stress-
induced cascade of JNKs [43]. Similarly, this cascade seems to be
activated primarily by stress-related stimuli, but is also known to
respond to signals transmitted by a wide variety of other receptors
and cellular processes [44,45]. Upon activation of the receptors, or
induction of stress conditions by environmental cues, the signals to
the p38 cascade are transmitted via adaptor proteins, small GTPases,
MAP4Ks and MAP3K that are usually similar to those functioning in
the JNK cascade. The differences in activation of these two cascades,
when existing, are mediated by speciﬁc scaffold proteins, compart-
mentalization, and variable substrates [2,46,47]. Upon transmission
by one or more components in the MAP3K level of the cascade, the
signals induce phosphorylation and activation of the MAPKK com-
ponents of the p38 cascade, which are mostly MKK3 and MKK6
[48], but under some circumstances, can also include MKK4 [49]. At
this stage, the signals are transmitted to the four isoforms (p38 α–δ;
p38s) and few functional alternative spliced forms at the MAPK
tier of the cascade (32–54 kDa). These components are activated
due to phosphorylation of the regulatory Thr and Tyr within the Thr-
Gly-Tyr domain in their activation loop. Interestingly, the activation
of p38s can also be mediated by autophosphorylation in a MAPKK-
independent manner. This type of activation is induced either by
stimulated interaction with the adaptor proteins Tab1 [50], by
phosphorylation of Tyr323 by ZAP-70 [51], or by interaction with
lipidic phosphatidyl inositol analogues [52], which in turn, catalyze
an enhanced autophosphorylation of p38s on its activatory residues.
This is an important mode of activation that allows additional and
unique levels of regulation of this cascade. Unlike JNK, the p38 cascade
has several components at its MAPKAPK tier, including MAPKAPK2-5
[53], MNK1/2 [54] and MSK1/2 [55]. MNK1/2 and MSK1 are shared
with the ERK1/2 cascade, and therefore, are a point of signal inte-
gration between these two MAPK cascades. Finally, the signals are
transmitted by the p38s, or the MAPKAPKs to target molecules, which
are responsible for the many processes that are induced and regulated
by the cascade.
Aside from their role in stress response [45], p38s play a central role
in the regulation of immunological effects [56], apoptotic [57], cellular
senescence [58], cell cycle checkpoints and even survival [59]. This
involvement in important processes predicts that dysregulation of the
cascade may have pathological manifestations. Indeed, p38s were
found to act as a key component in the induction of inﬂammation, and
are currently considered as important therapeutic targets for inﬂam-
mation-related diseases [60,61]. This role is also extended to other
diseases of the immune system, including autoimmune diseases and
others. In addition, p38s were shown to play a role in cardiovascular
Fig. 1. Schematic representation of the MAPK cascades and their nuclear targets. The main stimulants of the cascades are mentioned, although each cascade can be activated by
additional stimulations (see text for details).
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[45]. It was also implicated in the induction and maintenance of
neurodegenerative diseases [21], in diabetes [62], and even in cancer
[63]. Unlike the other MAPK cascades, p38s were primarily shown to
act as a tumor suppressor, acting through downregulation of Ras-
dependent and independent transformation, invasion, and also by
inducing apoptosis. However, in fewer cases, p38s were actually
shown to induce cancer progression, mainly due to its role in cancer-
associated inﬂammations or in the regulation of cell cycle [42]. The
nature of these different roles is not fully understood, but could result
from the different function of different p38 isoforms [63].
The ERK5 cascade is less studied and less understood than the other
MAPK cascades. As all other MAPK cascades, also this one is activated
by a large number of stimuli and receptors, but unlike the others, was
implicated equally in both stress andmitogenic signaling [64–66]. The
mechanism of activation of this cascade has not been fully elucidated
yet, but probably involves either adaptor proteins (e.g. Lad [67]), or
MAP4K (e.g. WNK1 [68]). Those components activate the kinases at
the MAP3K tier, consisting mainly of MEKK2/3 [69] and probably Cot1
[70]. These kinases activate the sole component in the MAPKK tier,
MEK5, by phosphorylating Ser and Thr in its activation loop. ERK5 is
the only component in the MAPK level of the cascade, and is also
known as a big MAPK (BMK) due to its relatively high molecular
weight (110 kDa). As ERK1/2, the activation of ERK5 is mediated by
phosphorylation of both Thr and Tyr residues within its Thr-Glu-Tyr
motif. However, despite the identical amino acids in the regulatory
domain, these MAPKs share very little similarity in their upstream
activators or physiological substrates. Upon stimulation, ERK5 can
transmit its signals to the one MAPKAPK that was reported thus far
(SGK1; [71]), and phosphorylate several cytoplasmic as well asnuclear targets. Interestingly, ERK5 can act as a transcription factor by
itself, which is mediated by DNA binding through its non-catalytic
region [72]. These downstream activities, allow ERK5 to induce and
regulate several physiological processes including proliferation [2],
angiogenesis [73], immunological processes [74], stress responses
[75] and probably additional processes. The cascade has also been
implicated in a few pathologies, including cancer [76,77]. However,
due to the small number of studies, the full scope of its functions is not
clear, and it is likely that ERK5 will be implicated in the future in
additional diseases.
3. Nuclear functions of the ERK1/2 cascade
The MAPK cascades participate in the regulation of essentially all
stimulated processes in the cell. In order to execute their functions,
the various MAPK components phosphorylate a large number of
substrates that are localized either in the cytoplasm, or in various
organelles, primarily the nucleus [7,9]. The nuclear functions of the
MAPK-dependent signals are important for the activation of tran-
scription factors necessary for the relevant gene expression. Other
roles of the nuclear activities, such as chromatin remodeling, direct
induction or suppression of transcription and regulation of cell cycle,
have been demonstrated as well. Therefore, nuclear translocation of
the MAPKs is essential for many of their activities. Indeed, speciﬁc
abrogation of ERK translocation into the nucleus by irreversible
cytoplasmic anchoring [78,79], MKP-2-dependent modulation of
nuclear MAPKs [80], or speciﬁc inhibition of the nuclear activity of
JNKs and p38s [81,82] blocked the progression of many of their
regulated cellular processes. In this review, we describe the main
nuclear activities of the various MAPK components, and their
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describe some of the nuclear functions of the ERK1/2 cascade, while
those of the other cascades are described in the next sections.
ERK1/2 execute their functions by activating a large number of
downstream targets that may vary under different conditions and cell
types. Currently, the number of identiﬁed substrates is as high as 200
(see initial list in [5]), although recent studies indicate that the actual
number is likely to be much higher [83]. Interestingly, the substrates
are localized in several cellular compartments, including the cyto-
plasm [84], cytoplasmic organelles such as mitochondria [85], Golgi
[86], endosomes/lysosomes [87], various membranes [88], and
particularly the nucleus. In fact, about half of the identiﬁed ERK1/2
substrates are nuclear proteins, and those participate in the regulation
of many stimulated nuclear processes including induction or
suppression of transcription, chromatin remodeling and nuclear
disintegration in mitosis. Some of the nuclear activities of ERK1/2
are described below.3.1. Regulation of immediate early genes
The main activity of ERK1/2 in the nucleus seems to be the
regulation of transcription factors. Indeed, one of the ﬁrst substrates
identiﬁed for ERK1/2 was the transcription factor Elk1 [89,90], which
is one of themain regulators of immediate early genes (IEG; [91]). The
rapid IEG transcription upon extracellular stimulation requires that
their transcription factors will be activated within minutes after
stimulation, and this occurs mostly by the ERK1/2 cascade. Indeed,
Elk1, which is a nuclear ETS-domain transcription factor, was found to
contain several MAPK consensus phosphorylation sites in its activa-
tion domain [92]. Stimulation of cells by various agents induces the
phosphorylation of Elk1 on no less than 6–9 distinct sites, and most of
these phosphorylations were shown to induce the activation of this
factor [93]. Importantly, the rapid phosphorylation of Elk1 by ERK1/2
occurs upon a direct binding of the two proteins, which like in many
other ERK1/2 substrates is mediated by two docking sites. One site is
the D-domain of Elk1, which interacts with the CD/CRS domain in
ERK1/2 [94], and the other is the hydrophobic DEF region in Elk1 [95],
which interacts with the hydrophobic interaction domain of ERK1/2.
One of the earliest transcriptional events regulated by Elk1 upon
stimulation, is the induction of the IEG c-Fos. This induction is
important for the proper progression of various cellular processes,
including proliferation and differentiation and seems to be dysregu-
lated within oncogenic transformation [96]. Thus, resting cells do not
express c-Fos, but this rapidly changes after stimulation when c-Fos is
induced for a few minutes up to several hours via a mechanism that
involves Elk1 activation. The changes in expression time of the c-Fos
protein are regulated by a combined action of protein kinases and
proteinases. Without phosphorylation, c-Fos is rapidly degraded, and
therefore, is expressed for only several minutes. However, phosphor-
ylation by nuclear ERK1/2 and their downstream RSKs on Ser374 and
Ser362 in the C-terminus of c-Fos is the ﬁrst step in its stabilization
[97]. The differences in c-Fos stability upon distinct stimulation
make it a good interpreter of differences in ERK1/2 kinetics of
activation, and therefore in the determination of ERK1/2-dependent
signaling speciﬁcity [98]. Moreover, the phosphorylation of c-Fos
might partially explain the induction of pathological processes
including oncogenic transformation that might be mediated only
upon prolonged ERK1/2 activation [97]. Similar phosphorylation by
ERK1/2 seems to be important for the stability and activity of
additional IEGs such as c-Myc and Fra1 [99], and the ERK1/2 cascade
can regulate other transcription factors by modulating ubiquityla-
tion and sumoylation as well [8]. Thus, ERK1/2 serve as key
regulators of transcription factors and IEGs in general, and AP-1 in
particular, under many conditions and in most cell lines and
organisms.3.2. Involvement of ERK1/2 in transcriptional suppression
Aside from the role of ERK1/2 in the induction of immediate early
transcription upon stimulation, they were also shown to play a role in
the regulation of many other transcription factors or transcription
repressors [5]. One of the main transcription repressors that are
regulated by ERK1/2 is the Ets2 repressor factor (Erf1), which
suppresses transcription in many resting cells [100]. Thus, in serum-
starved cells, Erf1 is dephosphorylated and located in the nucleus
where it suppresses transcription. Upon mitogenic and other
stimulations, Erf1 is phosphorylated by the translocated active
ERK1/2. This phosphorylation, in turn, induces CRM1-dependent
nuclear export of Erf1 [101,102], which thereby alleviates its
suppression of transcription [103]. The phosphorylation of Erf1 is
regulated mainly by two distinct FXF motifs that interact with the
hydrophobic DEF-binding domain in ERK1/2 [104]. Prevention of Erf1
phosphorylation was shown to reverse RAS-induced tumorigenicity
and to arrest ﬁbroblasts in the G0/G1 phase of the cell cycle. Hence,
ERK phosphorylation-dependent Erf1 export affects cell cycle pro-
gression, thus providing another link between the ERK1/2 cascade and
cellular proliferation [105].
Interestingly, the involvement of ERK1/2 in suppressing gene
activity is mediated not only through the regulation of transcription
factors/repressors, but also by the direct interaction of ERK1/2 with
DNA [20]. This unexpected effect was recently demonstrated by a
high-throughput examination of protein–DNA interaction proﬁles. A
comprehensive screen identiﬁed not less than 17,718 direct protein–
DNA interactions between 460 DNAmotifs and 4191 human proteins.
Many of these interactions were either known or expected, but some
were unanticipated interactions, either for known transcription
factors or for additional proteins that had not as yet been known to
interact with DNA. One of these proteins was ERK2, which was found
to bind to the DNA sequence G/CAAAG/C, independent of its catalytic
kinase activity. The authors showed that the interaction causes a
direct suppression of various transcriptional elements, including
gamma activated transcriptional element (GATE), which is responsi-
ble for the activity of the transcription factor C/enhancer binding
protein (EBP)-beta. Importantly, ERK2 was shown to mainly repress
interferon-γ-induced genes that are normally regulated by GATE, and
this suppression is relieved upon interferon-γ treatment, by depleting
the ERK2 molecules from the regulated promoters [20]. Thus, aside
from its well-known regulation of transcription factors, ERK2 can
regulate gene expression by activity-independent binding to promot-
er regions of some genes.3.3. Involvement of the ERK1/2 cascade in chromatin remodeling
Within the cell nucleus, the DNA is packaged into chromatin,
which is a compact structure composed of protein–DNA complexes
[106]. The double stranded DNA is coiled around an octamer of core
histones (H2A, H2B, H3 and H4) to form nucleosomes, which are
organized in higher order structures that are important for the proper
chromatin function. This structure is very condensed, and therefore,
not accessible by other proteins, such as transcription factors.
Consequently, “decompaction” and a change into active open
euchromatin is required in order to allow transcription. Indeed, in
response to stimulations, several distinct processes induce chromatin
remodeling in order to make the various target genes more accessible.
This includes histone acetylation, histone phosphorylation, poly ADP
ribosylation, changes in DNA conformation, and binding of other
proteins to the DNA. Some of these effects are regulated by the MAPK
cascades, including mostly ERK1/2 and p38s, and are required for
proper transcription and the induction of the MAPK-dependent
processes [107,108]. Three examples for such ERK1/2-mediated
effects are mentioned below.
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is mediated by its regulation of histone deacetylation, which is usually
associated with a compact chromatin structure and a repressed gene
transcription. Indeed, it was shown that histone deacetylase 4
(HDAC4), which is a member of a family of enzymes that catalyze
the removal of acetyl groups from core histones, directly interacts
with ERK1/2, and is probably phosphorylated by it [109]. In addition,
activation of the ERK1/2 cascade induced translocation of HDAC4 into
the nucleus. These results indicate that ERK1/2 participate in a process
that leads to chromatin condensation, and thereby, induce a negative
feedback loop that is required for its long-term desensitization upon
stimulation. Another way bywhich the ERK1/2 cascademaymodulate
chromatin arrangements is by MSK-induced phosphorylation of the
chromatin-arranging proteins histone H3 and HMG-14 [106,107,110].
RSK2 was implicated in the phosphorylation of histone H3 as well, but
at this stage, this observation is still controversial [8]. This phosphor-
ylation then, is able to induce looser structure of the chromatin and
accelerate a stimulated transcription.
ERK1/2 were also shown to induce chromatin remodeling by its
non-conventional inﬂuence on PolyADP-ribose polymerase 1
(PARP1). This protein catalyzes a polyADP-ribosylation of nuclear
proteins that affects chromatin structure. It was shown that the
catalytic activity of this protein is stimulated not only by DNA strand
breaks, but also by the ERK1/2 cascade [111]. Interestingly, the effect
of ERK1/2 on PARP1 activity was not mediated by phosphorylation
of the protein, but rather was induced by a direct interaction with
ERK1/2. In addition to its possible effects on chromatin function, the
activated PARP-1 also increased ERK2-catalyzed phosphorylation of
Elk1, which may be important for the enhanced transcriptional
activity of the latter. Similar non-catalytic activation of nuclear
proteins by ERK1/2 was also demonstrated in the case of topoisome-
rase 2α [112], which is activated by this interaction to induce
modulation of the DNA structure downstream of the ERK1/2 cascade.
Thus, the ERK1/2 cascade is one of the regulators of chromatin
remodeling that plays a role in the induction or suppression of
transcription. However, at this stage, it seems that this process is
mainly regulated by other signaling pathways, and the ERK1/2
cascade plays only an accessory role or is limited to distinct cell
lines and conditions.
3.4. Regulation of nuclear import by the ERK1/2 cascade
Another mechanism by which the ERK1/2 cascade regulates
cellular processes is by affecting the general nuclear import
machinery. The nucleus is separated from the cytoplasm by a
double membrane envelope. Cytoplasmatic/nuclear shuttling of
molecules through this envelope occurs via specialized nuclear
pore complexes (NPC) that coordinate nucleo-cytoplasmic exchange,
ensure high selectivity and support proper cytoplasmatic/nuclear
molecular balance ([113]; see also description in Section 5). The NPC
is a large macromolecular complex, composed of more than 100
proteins that are termed nucleoporins (NUPs) in eukaryotes [114–
116]. Interestingly, many studies over the past decade demonstrated
a direct interaction of NUPs with ERK1/2. Initial studies showed
binding of the kinases to NUP214 [117] and NUP153 [118], which
were ﬁrst suggested to induce a carrier-independent nuclear import/
export of ERK1/2. However, the ﬁnding that ERK2 can phosphorylate
NUP153 in vitro [119], and the elucidation of a distinct mechanism
of nuclear translocation [120], suggests that the interaction with
these NUPs may affect nuclear shuttling of additional proteins and
not only ERK1/2.
The above NUPs are not the only targets of ERK1/2 in the NPC.
Another NUP that is phosphorylated by the ERK1/2 cascade is the
NUP “translocated promoter region (TPR)”, which was identiﬁed as
an ERK substrate by an engineered kinase and ATP analogues
methodology [121]. It was later shown that the phosphorylation ofTPR is required for its binding to ERK1/2, which therefore allows
recruitment or ERK1/2 to the NPCs [122]. Similarly, it was also
shown that ERK1/2, as well as other MAPKs, constantly interact
with NPCs and phosphorylate an additional NUP, termed NUP30
[123]. Although these studies implicated ERK1/2 in NUP regulation,
they did not provide any clue regarding the exact function of all
these NUP phosphorylations. However, a more informative study
has recently identiﬁed NUP50 as a bona ﬁde substrate of ERK1/2
[124]. It was further shown that ERK1/2 phosphorylate the FG
repeat of this NUP as well as other NUPs, and this phosphorylation
reduces their afﬁnity for importin-β family proteins. Importantly,
ERK phosphorylation of NUP50 resulted in impaired translocation of
importin-β and transportin, strongly suggesting that the ERK1/2
cascade indeed regulates the general nucleocytoplasmic transport
machinery by phosphorylating NUPs.
The effect of the ERK1/2 cascade on protein shuttling is not only
mediated by NUP phosphorylation, but also by the regulation of
RanGTP distribution [125]. Ran is a small GTPase, which is localized in
its active, GTP-bound form predominantly in the nucleus [126]. The
inactive form of Ran is localized mainly in the cytoplasm, and the
resulting Ran gradient regulates import and export of proteins
through NPCs. One of the regulators of RanGTP gradient is Ran-
binding protein 3 (RanBP3), which regulates nuclear export via CRM1
[127]. Interestingly, RSKs, acting downstream of ERK1/2, interact
with, phosphorylate and regulate the activity of RanBP3, and thereby
regulate general nuclear shuttling and cell fate [125]. This phos-
phorylation can be mediated by the AKT pathway as well, suggesting
that the effect of RanBP3 phosphorylation is of general importance
upon distinct stimulation [125]. Collectively, these studies present
new and exciting ways of regulation of various nuclear shuttling
machineries by the ERK1/2 cascade. These mechanisms provide an
additional way for determination of signaling speciﬁcity of the
cascades, which is important for cell fate determination upon
various stimulations.3.5. Direct involvement of MEK1/2 in nuclear processes
MEK1/2 are unique 45/46 kDa dual speciﬁcity kinases that appear
to phosphorylate only ERK1/2, and therefore, are the speciﬁcity
determinants of their cascade [128,129]. Initial studies described
MEK1 as a cytoplasm-resident protein, both in resting cells and after
stimulation, in contrast to its substrates ERK1/2 that were found in
the nucleus upon stimulation [130,131]. This subcellular distribution
was attributed to an association with cytoplasmic anchoring
proteins such as KSR [132], as well as to a leucine-rich sequence in
the N-terminus of the protein that acts as a CRM1-dependent
nuclear export signal (NES; [133]). This sequence was initially
suggested to act as a safety mechanism to secure the cytoplasmic
localization of MEK1, which is important for its function, as well as
that of MEK2, as anchoring proteins of ERK1/2 in the cytoplasm
[134,135]. In support of that, when the NES is interrupted by
replacing the sequence's Leu with Ala residues, MEK1 is found both
in the nucleus and in the cytoplasm, in contrast to the wild-type
MEK1, which is found exclusively in the cytoplasm [136]. However,
it was later shown that MEK1 and probably MEK2 could rapidly
translocate into the nucleus upon cellular stimulation [136–138].
Thus, initiation of signaling via the cascade causes MEK1/2 to detach
from ERK1/2 and from other anchoring molecules, and translocate
separately from ERK1/2 into the nucleus. Unlike ERK1/2 that can be
retained in the nucleus for minutes to hours after stimulation, most
MEK1/2 molecules are rapidly exported back to the cytoplasm
shortly after translocation, giving rise to the apparent constant
cytoplasmic distribution. This rapid, CRM1-dependent export is
important for mediating the functions of ERK1/2 cascade-dependent
processes. Therefore, it became important to study the role and
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resting and stimulated cells.
Although the role of this rapid MEK1/2 shuttle is not fully
understood yet, some studies may have shed light on this issue.
Since MEK1/2 were shown to be very speciﬁc towards ERK1/2, it
was thought that the translocation might affect nuclear ERK1/2
molecules. Indeed, constant nuclear localization was reported for
alternatively spliced isoforms of ERK1, namely ERK1b [17], and to
some extent ERK1c in G1/S phase of the cell cycle [18]. The
phosphorylation of these isoforms is MEK1/2-dependent, and
therefore is likely to involve the translocated active MEK1/2
molecules. In addition, it was shown that translocated MEK1, and
probably MEK2 may be involved in the export of ERK1/2 out of the
nucleus at late stages after stimulation [139]. Thus, nuclear inactive
MEK1/2, mostly generated by dephosphorylation of the translocated
molecules, are able to re-bind to inactive ERK1/2 molecules in this
location. This is followed by interaction of the NES of MEK1/2 with
CRM1 and a rapid export of the complex out of the nucleus, resulting
in the resetting of the ERK1/2 cascade. Interestingly, it was later
shown that MEK1 could induce export of other nuclear proteins
beside ERK1/2. These include the nuclear receptor PPARγ [140],
whose nuclear export upon mitogenic stimulation participates in its
functional inactivation. Finally, one study reported that MEK1/2 can
be identiﬁed within the nucleus of muscle cells where they bind the
nuclear MyoD transcriptional complex and thereby repress its
activity [141]. These ﬁndings suggest that the nuclear translocation
of MEK1/2 has an important physiological role, but additional
studies are required to elucidate the full scope of this effect in
various systems.
4. Nuclear functions of the other MAPK cascades
Although less studied than the “prototypic ERK1/2 cascade” [48],
the nuclear activities of the JNK, p38 and ERK5 cascades have been
implicated in various important cellular processes as well. As was
shown for ERK1/2, also the other MAPKs regulate transcription,
chromatin remodeling, stability of nuclear proteins and other nuclear
processes [6,8]. These processes are regulated by a set of nuclear
substrates, which are either targeted only by one of the cascades, or
more frequently, by two and even three of the MAPKs. Examples for
the latter case are Elk1, which is regulated by ERK1/2, JNKs and p38s
[142]; c-Fos, by ERK1/2 and ERK5 [143]; and c-Jun, which is regulated
by JNKs and ERK1/2 [144]. The ability of the various cascades to
regulate the activity of similar substrates is not very surprising, since
the different components in the MAPK and most MAPKAPKs share the
same consensus phosphorylation site (Pro-Xaa-Ser/Thr-Pro for
MAPKs [145,146], and basic amino acid N-terminal of Ser/Thr for
MAPKAPKs [147,148]). However, it is not very clear how the
activation of these nuclear targets by distinct MAPK cascades still
results in distinct outcomes. These distinct speciﬁcities may be
mediated by spatio-temporal differences, interaction with distinct
scaffold proteins, distinct interaction afﬁnities with various sub-
strates, and regulation by additional nuclear components [1]. Overall,
the various phosphorylations on similar, as well as distinct targets
lead to integration of the MAPK and other signals, and allow
progression of nuclear processes such as transcription [44], chromatin
remodeling [149], protein stability [150], subcellular localization [81],
and even cell cycle progression [151]. In this section, we cover some of
the nuclear processes that seem to be preferentially induced by the
stress-activated MAPK cascades.
4.1. Regulation of transcription factors by stress-activated cascades
Over the past years, it was reported that JNKs, p38s and their
responsive MAPKAPKs directly regulate a wide range of transcription
factors. Some of the main transcription factors regulated by JNKs are:c-Jun, JunB, JunD, ATF2, p53, JDP2, and c-Myc [152], and by p38s: ATF-
1/2/6, Sap1, CHOP, p53, C/EBP, MEF2C, MEF2A, and HBP1 [44]. The
activation of all these transcription factors is likely to regulate
different aspects of the response of cells to various stresses and
other stimuli. Here we focus on the phosphorylation and activation of
three well-studied transcription factors, c-Jun, MEF2A, and p53. These
may be considered as prototype transcription factors, and therefore,
their activation probably exempliﬁes the mechanism of activation of
other members of the group as well.
The ﬁrst identiﬁed, and one of the best-known transcription
factors regulated by JNKs, is c-Jun, which gave JNKs their name [153].
c-Jun is constantly expressed in resting, as well as stimulated cells. In
order to exert its activity upon stimulation, c-Jun interacts with other
transcription factors such as c-Fos, and ATF to form a complex known
as “activator protein 1” (AP-1) [154]. In addition, the activation of c-
Jun requires phosphorylation of its transactivation domain, mainly on
Ser63 and Ser73 [155], but also on Thr91 and Thr93 [144]. This
phosphorylation, which is mediated by all three JNK isoforms and to
some extent by other MAPKs, induces the full transcriptional activity
within the AP-1 complex, independent of DNA binding [156]. Aside
from the induction of transactivation, the phosphorylation was also
shown to increase the half-life of c-Jun protein [157], which is
important for the timing of the transcriptional response. Therefore,
the phosphorylation of c-Jun is a central mechanism by which JNKs
and other MAPKs induce their responses upon various extracellular
stimulations.
The induction of c-Jun phosphorylation is important for the
regulation of many distinct cellular processes, ranging from
proliferation to apoptosis. However, MAPKs often modulate the
activity of speciﬁc transcription factors that regulate the activity of
more limited number of cellular processes. An example of such an
effect is MEF2A, which is phosphorylated by two isoforms of p38,
p38α and p38β2, and to some extent by ERK5 [158,159]. This unique
speciﬁcity can be mediated, in principle, by scaffold proteins or by
speciﬁc docking interactions to the substrates [160,161]. In the case
of MEF2A, it was shown that the second possibility prevails, and this
occurs due to variations in the docking (D) domains of the
transcription factor, which secured interactions exclusively with
relevant MAPKs. In similarity to the phosphorylation of c-Jun
described above, the phosphorylation by MAPKs facilitates the
activity and stability of MEF2A, thereby promoting its function in
several cells including cardiac muscles, neurons and T cells [162].
An additional transcription factor that plays a central role in the
cellular response to stress and is phosphorylated by MAPKs, is p53.
In unstressed cells, p53 is maintained at low expression levels
through targeted degradation. However, genotoxic agents and other
stresses that stabilize the p53 protein induce its phosphorylation
on various residues, and activate its transcriptional activity. This
activation leads either to growth arrest, mostly at the G1/S phase,
or often to apoptosis, which is required for the elimination of
hyper-mutagenized cells [163,164]. The phosphorylation of p53
occurs on multiple sites and is mediated by several protein kinases,
including JNKs [165], p38s [166], and even ERK1/2 [167].
Interestingly, the distinct MAPKs phosphorylate several sites on
p53, as JNKs were reported to phosphorylate Ser6 and Ser36, which
are both correlated with elevated p53 activity. Interestingly, this
phosphorylation seems to be mediated mainly by the interacting
JNK2, while JNK1 does not phosphorylate these residues. Rather,
activation of JNK1 in this system seems to accelerate the activation
of JNK2, which in turn is able to phosphorylate p53 and induce
apoptosis [168]. ERK1/2, phosphorylate Thr73 and Thr83, the
functions of which are not fully understood, and Ser15, which
upon phosphorylation by JNKs and also by p38s induces the
activation of p53. More studies are required to better characterize
p53 phosphorylation by MAPKs and the speciﬁc outcomes of these
phosphorylations.
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Another subgroup of transcription factors that is regulated by
MAPK cascades is the family of nuclear receptors, which include
estrogen receptor (ER), glucocorticoid receptor (GR), peroxisome
proliferator-activated receptor (PPAR), androgen receptor (AR) and
retinoic acid receptor (RAR). These nuclear receptors are usually
activated by speciﬁc ligands, and the phosphorylation by MAPKs
does not always induce their activity, but rather modulate it. This
difference from the activation of the above transcription factors
prompted their description under this separate subsection. Although
the ERK1/2 cascade seems to be a major regulator of these nuclear
receptors [169,170], over the past years it became clear that other
MAPKs are centrally involved in the regulation of some of the
receptors as well. One way by which these MAPKs inﬂuence the
nuclear receptor is through modulating the transcriptional activity
of the latter. For example, it was shown that PPARα is phosphor-
ylated by p38s upon ischemia, hypoxia, and other stresses of cardiac
myocytes [171,172]. This phosphorylation leads to a signiﬁcantly
enhanced ligand-dependent transactivation, and therefore, en-
hanced expression of energy metabolic genes [171]. In addition,
PPARα phosphorylation by p38s was shown to mediate adiponectin
signaling, which is important for the regulation of fatty acid
oxidation in muscle cells [172].
Another nuclear receptor that is regulated by the p38 cascade is
the retinoic acid receptor gamma (RARγ). A well-studied effect of p38
is the direct phosphorylation of RARγ, which facilitates the recruit-
ment of the coactivator SUG1, and consequently the transactivation of
the nuclear receptor [173]. However, it was shown that the same
phosphorylation of RARγ is important also for the late degradation
and downregulation of RARγ. Therefore, this phosphorylation by p38s
may be important not only for the activation, but also for the
downregulation and the transactivation-linked turnover of RARγ.
Moreover, RAR signaling may be modulated by p38-mediated
phosphorylation of the interacting protein SRC-3, which was shown
to affect the fate of RAR signaling in embryonic cortical neurons [174].
In view of the above, p38s seem to be central, multifaceted regulators
of the nuclear receptors PPAR and RAR in various systems and
conditions. Importantly, the unexpected ability of MAPKs to regulate
nuclear receptors by phosphorylation of their interacting regulators is
not limited to RAR. Thus, it was shown that p38s stimulate estrogen-
dependent transcription through phosphorylation and potentiation of
the p160 coactivator GR-interacting protein 1. This elevation in
transcription seems to enhance estrogen-mediated proliferation and
maybe important for oncogenic transformation as well [175]. More
such indirect effects on other nuclear receptors such as ER and AR still
await clariﬁcation.
As mentioned regarding RARγ, phosphorylation by stress-
activated MAPKs does not only activate the nuclear receptors, but
may also participate in their inactivation and downregulation. One
example of the downregulation of nuclear receptors is the AR, which
is phosphorylated on Ser650 upon stress stimulation by both JNKs
and p38s [176]. This phosphorylation induces nuclear export of AR,
and therefore, reduces its transcriptional activity, indicating that
JNKs and p38s are both negative regulators of AR activity. However,
in most cases, the effects by the p38 and JNK cascade are distinct
from each other, as the p38 cascade often enhances the activity of
the nuclear receptors (as above), whereas the JNK cascade down-
regulates them. Example for inhibitory effects of the JNK cascade is
the regulation of the glucocorticoid receptor. It was shown that upon
UV exposure, GR is phosphorylated by JNKs on Ser226, and this
induces nuclear export of the nuclear receptor in the absence of the
ligand for GR, dexamethasone [177]. Therefore, this phosphorylation
is important for the termination of GR-mediated transcription after
stress response. Aside from the inhibitory effects on subcellular
localization of the nuclear receptors, JNKs may negatively regulatethe nuclear receptors by a direct phosphorylation. Such an effect was
reported for PPARγ that is phosphorylated on its inhibitory Ser82 by
JNKs, similarly to the negative regulation by ERK1/2 [178]. In
addition, JNKs are also involved in the inhibition of RXRα and RARα
activities. In the case of RXRα, JNKs phosphorylation inhibits the
activity of the nuclear receptor upon treatment with arsenic trioxide
[179]. In the case of RAR, JNK phosphorylation induces proteasomal
degradation of RARα, thereby promoting aberrant RAR signaling in
lung cancer cells [180]. These examples indicate that nuclear
receptors are important MAPK targets, and their phosphorylation
modulates the activity of these transcription factors independently
of their corresponding ligand-induced activation.4.3. Regulation of the subcellular localization of transcription factors by
MAPKs
One way for the regulation of transcription factors by MAPKs is
via the modulation of their subcellular localization [181]. Such a
regulation was described above for the nuclear export of the
transcription factors PPARγ and GR, which are regulated by MEK1/
2, and JNKs respectively. In the past years, it was shown that this
type of regulation, mainly by the stress activated MAPKs, plays an
important role in the regulation of additional transcription factors
as well. One of the best examples for such a regulation is the
transcription factor NFAT. The activity of this factor is usually
induced by elevated cellular calcium concentrations, which induce
nuclear translocation of the otherwise cytoplasmic protein [182]. In
most cases, the nuclear translocation is mediated by interaction with
the phosphatase PP2B, which translocates to the nucleus along with
NFAT. At later stages after stimulation when the signals are reduced,
NFAT is phosphorylated again, and this allows its export back to the
cytoplasm. A group of kinases that mediate the later phosphoryla-
tion is that of p38s, which inhibit NFAT action upon stress
stimulation [182]. Interestingly, the subcellular localization of the
different isoforms of NFAT is not regulated exclusively by the p38
cascade, but by other signaling cascades including ERK5 and
mTORC1 [183] as well. It was shown that each of these kinases can
phosphorylate NFATc4 on Ser168 and Ser170, and enhance nuclear
export of this transcription factor. In addition, NFATc4 is phosphor-
ylated by ERK5, which primes NFATc4 to phosphorylation by CK1.
These ERK5 and CK1 phosphorylations then cooperate to stabilize
the transcription factor, and are probably dispensable for the
determination of its localization.
Another transcription factor, of which the cellular localization is
regulated mainly by MAPKs, is Foxo3a [184]. This regulation was
demonstrated in the processes of muscle atrophy, which involves
loss of muscle mass due to activation of ubiquitin-dependent
proteasomal protein degradation. Nuclear Foxo3a seems to partic-
ipate in this process by activation of the ubiquitin ligase Atrogin-1,
further allowing progression of atrophy [184]. JNKs, or p38s
participate in the regulation of Foxo3a during these processes
by inducing its CRM1-mediated nuclear export, and this effect is not
related to its nuclear translocation that is mediated independently
by the PI3K/AKT activity. Stress-activated MAPKs control Foxo3a
activity also by modulation of its ubiquitylation in muscle
cells, which demonstrate a multifaceted regulation of atrophy
and other muscle-speciﬁc processes. Another important example
for the effect of JNKs on subcellular localization of regulators of
transcription is the phosphorylation of β-catenin, which prevents
its nuclear accumulation [185]. This prevention of nuclear
translocation inhibits the interaction of β-catenin with its nuclear
effector, the transcription factor TCF. Thus, the effects of MAPKs
on the subcellular localization of transcription factors and
regulators consist an important layer of regulation of various cellular
processes.
1626 A. Plotnikov et al. / Biochimica et Biophysica Acta 1813 (2011) 1619–1633As described for ERK1/2 above, another mechanism by which
MAPKs can regulate the nuclear shuttling of transcription factors upon
stimulation is via phosphorylation of NUPs. In this sense, it was
shown that similarly to ERK1/2, JNKs and p38s are constitutively
associated with NPCs, and therefore, may regulate nuclear pore
functions [123]. Indeed it was shown that JNKs phosphorylate
NUP214, which may participate in the induction of neuronal
apoptosis [186], and p38s (and ERK1/2) participate in the regulation
of nuclear import upon mechanical stretching [187]. Moreover, p38s
may regulate nuclear import by disrupting RanGTP gradient upon
hyperosmotic stress [188]. This change in the RanGTP gradient was
prevented by p38 inhibitors, supporting the role of this MAPK in the
general regulatory process of protein accumulation in the nucleus.
Thus, the localization of transcription factors is heavily regulated
by MAPKs, but the full scope of this regulation requires further
clariﬁcation.
4.4. ERK5 is a potent transcription factor
As described above, components of the MAPK cascades usually
phosphorylate and modulate the activity of a large number of
transcription factors. However, some MAPKs can also act as either
transcription factors (ERK5; [72]) or transcriptional repressors by
themselves (ERK1/2; [20]). In this sense, the action of ERK5 as a
transcription factor is a unique example of a dual activity enzyme
that not only regulates the action of many transcription factors (e.g.
Sap1a, c-Fos, Fra1, and MEF2), but also acts as one by itself [65].
ERK5 has a large, unique C-terminal-half, which is not found in
other MAPKs, and contains two proline-rich domains and a bipartite
NLS. This C-terminal part demonstrates a very little similarity with
other proteins, and was shown to exhibit potent intrinsic stimulus-
dependent transcriptional activity [72]. This transcriptional activa-
tion domain of ERK5 is required for maximal MEF2 activity in
response to calcium ﬂux in T cells, and for the activation of the
endogenous Nur77 gene, when recruited to the Nur77 promoter via
MEF2 sites. Later it was also shown that the transactivation activity
of ERK5 is enhanced upon phosphorylation and activation of the
ERK5 kinase activity [189]. Furthermore, active ERK5 can autopho-
sphorylate itself at the C-terminal-half, and this was found to be
necessary for the enhancement of the transactivation activity of the
protein. Moreover, this activity is enhanced by the constant nuclear
localization of ERK5 in most cells [190], and is likely to exert many
stimulated activities of ERK5 and possibly of other protein kinases.
Thus, ERK5 is a dual activity protein that is activated upon
stimulation, autophosphorylates its C-terminus to enhance its
transcriptional activity, and thereby transcribes genes that are
necessary for various cellular processes.
5. Mechanisms of ERK5 and ERK1/2 translocation into the nucleus
In resting cells, the components of the ERK1/2 cascade are
localized primarily in the cytoplasm, where they are retained mainly
due to interaction with various anchoring proteins [7]. Upon
stimulation, these components are rapidly activated and change
their location in order to execute their functions. Thus, Rafs move
mainly to the plasma membranes, but also to other cellular
membranes, where they are activated by Ras GTPases. On the other
hand, MEK1/2, and ERK1/2 translocate to the nucleus shortly after
stimulation. MEK1/2 are rapidly exported out of this compartment by
their N-terminal NES, while ERK1/2 are retained in that location for
many minutes or even hours. The translocation of these components
into the nucleus is essential for their proper activity and especially for
the induction of proliferation, but the mechanism that allows this
translocation is not fully understood. As for the ERK5 cascade, the
subcellular localization of its components seems to vary in different
cell lines. In most cell lines examined, ERK5 and MEK5 are constantlylocalized in the nucleus, and the activating signals reach them through
the cytoplasmic MEKK2 that translocates into the nucleus upon
stimulation [190,191]. However, in other cells, the distribution of
these components seems to resemble that of ERK1/2, whereby ERK5 is
cytoplasmic in resting cells, and translocates to the nucleus upon
stimulation [192,193]. Although it is likely that similarly to ERK1/2,
JNKs and p38s are cytoplasmic in resting cells and translocate to the
nucleus upon stimulation, the current knowledge about their
localization is very limited. Several recent studies presented new
information on the mechanism of nuclear translocation of ERK1/2 and
ERK5, which seems to be distinct from the canonical NLS-dependent
shuttling of housekeeping proteins. In this section we describe the
canonical NLS-dependent, as well as the ERK1/2 and ERK5 mecha-
nisms of translocation; explain the differences between them; and
discuss their role as an unexpected layer of regulation in stimulated
cellular processes.5.1. The canonical, NLS/importin-α/β-dependent, mechanism of nuclear
shuttling
As mentioned above, shuttling of molecules through the nuclear
envelope occurs via specialized nuclear pore complexes (NPC) that
coordinate nucleo-cytoplasmic exchange [113]. Each NPC complex
allows a relatively free transport in and out of the nucleus of ions,
metabolites, and small macromolecules (up to 40 kDa). These small
molecules usually shuttle via the NUPs by passive diffusion, whereas
big proteins and RNA must utilize speciﬁc and active transportation
mechanisms for this purpose. The ﬁrst step of active transport of
macromolecules from the cytoplasm to the nucleus through NPCs is
their interaction with special shuttling transport factors — karyo-
pherins (importins and transportins). Proteins that need to be
transported (cargo proteins) include newly translated nuclear
proteins upon their release from the ribosomes, or signaling proteins,
which undergo acute nuclear translocation upon cellular stimulation.
The best-known mechanism of translocation of many of these
proteins is based on their interaction with importin-α/β that rapidly
escort them into the nucleus. This interaction is usually mediated by
a speciﬁc nuclear localization signal (NLS) within the sequence of the
cargo proteins [194].
NLS is usually composed of a cluster of 4 or more basic amino
acids (e.g. PKKKRKV in SV40 large T-antigen [195]), but in many
cases contains even an additional separated basic cluster (e.g. KR
[PAATKKAGQA]KKKK in nucleoplasmin [196]), which turn it to a
“bipartite basic NLS”. Other non-canonical NLSs were identiﬁed as
well [197], but their mechanism of action is still unclear. The various
NLSs bind to a speciﬁc sequence in importin-α, which in turn
recruits importin-β to the complex. The role of importin-β is to
interact with NUPs within the NPC and allow the proper sliding of
the transporting complex through the pores [198]. Subsequently, the
complex is dissociated at the nuclear face by the small GTPase (Ran)
that is localized at this site in its GTP bound form, which allows its
action on the transported complex. The dissociated importins are
then exported from the nucleus by the CRM1 export machinery
[101], while the dissociated cargo is freed to execute its nuclear
functions. Thus, this classical mechanism that shuttles many
proteins into the nucleus is important for the proper localization
of most house-keeping proteins, but is responsible for the stimulated
nuclear shuttling of only few signaling proteins including NFkB [199]
and ERK5 [65] (see below). Most signaling molecules do not contain
the canonical NLS, and their mechanism of translocation is currently
under investigation. Export of proteins out of the nucleus is
mediated by a unique sequence termed nuclear export signal (NES
[200]) that interacts with exportins such as CRM1 [101,102]. This
induces an efﬁcient nuclear export of the interacting proteins to the
cytoplasm.
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Most of the MAPKs do not contain the canonical NLS in their
sequence, and therefore, are likely to use a specialized mechanism for
their stimulus-dependent translocation. However, ERK5 does contain
two NLSs in its C-terminal non-kinase domain, which might be used
for the canonical mode of nuclear shuttling. As mentioned above,
although ERK5 is localized in the nucleus of many cells, there are
systems in which it is localized in the cytoplasm and translocates into
the nucleus upon stimulation. This translocation requires phosphor-
ylation by the upstream MEK5, which is essential not only for the
activation of ERK5, but also for conformational changes that allow the
nuclear accumulation [193]. Interestingly, aside from its NLSs, ERK5
contains one NES in its C-terminal domain, which seems to play an
important role in the subcellular localization of the kinase. In resting
cells, ERK5 is folded in such a way that its N-terminal domain is tightly
bound to the C-terminal part. This folding exposes both the NES and
the NLSs of the ERK5, but since the CRM1 system that interacts with
the NES is more potent than NLS/importin α/β activity, the net result
of this folding is a predominant cytoplasmic localization. After
stimulation, phosphorylation of the TEY motif in the kinase domain
of the ERK5 disrupts the intramolecular interaction and hinders the
NES domain, thus preventing ERK5 interaction with the nuclear
export machinery. As a result, ERK5 translocates into the nucleus due
to its NLSs, which continue to be exposed [193]. Thus, cytoplasmic
ERK5 utilizes the canonical NLS/importin-α/β for its translocation,
whereas in cells where MEK5 and ERK5 are constitutively nuclear,
their activation is induced by translocation of active MEKK2/3 [190].
These MAP3Ks' sequence does not contain a canonical NLS, and
therefore, its mechanism of translocation is not clear. Mechanisms of
NLS/importin-α/β-independent translocation are described below,
and it is possible that one or two of them are used by MEKK2/3 for
their stimulated translocation.
5.3. NLS-independent translocation mechanisms
Unlike the NLS-containing components, many signaling proteins
translocate to the nucleus shortly after stimulation using distinct,
importin-α/β-independent mechanisms. Due to the rapid nuclear
translocation and the size of most proteins (N40 kDa), it is unlikely
that the translocation of these proteins is mediated by a passive
diffusion. Previous studies on nuclear translocation of signaling
proteins suggested various possible NLS-independent mechanisms,
which were later suggested to be also important for the translocation
of MAPKs under various conditions. One such signaling protein is PKA,
which transmits signals of many hormones, and thereby, regulates
metabolism, differentiation and other cellular processes [201]. The
catalytic subunit of PKA was shown to accumulate in the nucleus
shortly after stimulation, and such a rapid translocation suggests that
PKA uses different mechanism in addition to the passive diffusion that
had been previously suggested [202]. Another type of signaling
molecules that translocate to the nucleus upon stimulation is signal
transducers and activators of transcription (STATs), which are
localized in the cytoplasm of resting cells. Upon stimulation, STATs
undergo phosphorylation by the protein tyrosine kinase JAK, allowing
them to translocate to the nucleus, where they regulate gene
expression [203]. Since STATs do not contain active canonical NLS
motif, the mechanism of their nuclear translocation is not clear. One
suggested mechanism is that STAT1 and STAT2 dimerize upon
stimulation, and this dimerization creates a structural NLS motif by
bringing together residues from both proteins [204]. It has also been
suggested that NLS-containing signaling proteins other than impor-
tin-α/β escort STATs to the nucleus upon stimulation [205,206]. A
third option is that STATs interact by themselves with NUPs, and
therefore, do not require the assistance of importins for the
translocation (as suggested for SMADs [207], β-catenin [208] andpossibly other signaling components [209]). However, none of the
mechanisms, for any of these proteins, was properly veriﬁed, and
other mechanisms are likely to exist as well.
5.4. Studies on the translocation of ERK1/2 into the nucleus
In addition to the above-mentioned signaling molecules, ERK1/2,
as well as MEK1/2 translocate into the nucleus in an NLS- and
importin-α/β-independent manner [7,9]. The onset of translocation
of these molecules is relatively fast (5–15 min after stimulation
[130,136,137]), and always transient. However, although ERK1/2
molecules stay in the nucleus from several minutes to hours, MEK1/2
are exported from this location much faster, due to their N-terminal
NES [133]. As mentioned above, the translocation of both ERK1/2 and
MEK1/2 into the nucleus was shown to be essential for proliferation
and probably other physiological functions of the ERK1/2 cascade
[79,138]. This importance of nuclear ERK1/2 in proliferation prompted
many studies on the molecular mechanism of their nuclear shuttling.
In these studies it was shown that ERK1/2 are localized in the
cytoplasm of resting cells due to interaction with anchoring proteins,
such as microtubules [210], MEK1, [134,135], phosphatases [211], and
others [160]. Upon stimulation, most ERK1/2 molecules are detached
from their cytoplasmic anchors [212] and rapidly translocate into the
nucleus, either by passive diffusion or by active transport [213]. The
active transport was initially suggested to involve homo-dimerization
of the ERK1/2 molecules [213,214]. However, these ﬁndings were
later disputed [212,215], and currently the dimerization of ERK1/2 is
thought to be essential for cytoplasmic signaling upon scaffold
interactions [216].
Further studies claimed that despite the lack of NLS, ERK1/2 trans-
location might be aided in mammalian cells by components of the
canonical nuclear translocationmachinery [213], and in Drosophila, by
D-Importin-7 (DIM-7) plus importin-β [217]. It was also shown that
the translocation might be calcium dependent, which suggests that
the mechanism of translocation might be dependent, at least in part,
on calcium immobilization [218]. Another, more recent, suggestion for
a possible translocation mechanism was that, similar to the possible
translocation of β-catenin mentioned above, ERK1/2 may translocate
to the nucleus by a direct interaction with nuclear pore proteins
[117,118]. However, some of these suggestions were not rigorously
veriﬁed, and others turned out to be speciﬁc to only a few cell lines.
These uncertainties, as well as mutational analysis, prompted the
suggestions that ERK1/2 translocate into the nucleus by multiple
mechanisms, each of which might act in different cell lines or upon
various stimulations [219,220].
5.5. The NTS/importin7 mechanism of ERK1/2 translocation
In order to elucidate the mechanism(s) of ERK1/2 translocation
into the nucleus, our group mutated residues in the kinase insert
domain (KID) of ERK2, which had previously been implicated in the
regulation of its subcellular localization [220]. This study identiﬁed
a critical sequence for the stimulated, as well as non-stimulated,
ERK1/2 translocation [9,120]. The sequence contained two Ser
residues separated by a Pro (Ser-Pro-Ser; SPS; 244–246 of ERK2)
that, when mutated to Ala or deleted, prevented the translocation.
The identiﬁcation of phosphorylatable residues within an area that
may serve as a consensus phosphorylation site for several kinases,
suggested that the region might be phosphorylated in order to
execute its role in nuclear translocation. Mass spectroscopic analysis,
as well as anti p-SPS antibody that was raised, conﬁrmed that this
site is indeed phosphorylated upon stimulation. As expected,
phosphomimetic mutations of the two Ser residues resulted in
accelerated nuclear translocation, and thereby veriﬁed the impor-
tance of the Ser-Pro-Ser phosphorylation for the translocation
process. It should be noted that the phosphorylation of Ser246
Fig. 2. The mechanism of ERK1/2 translocation into the nucleus. 1) In resting cells, ERK1/2 are retained in the cytoplasm by speciﬁc anchors. 2) Cellular stimulation results in
phosphorylation of the TEYmotif of ERK1/2 by activeMEK1/2. This leads to detachment of ERK1/2 from the cytoplasmic anchors and exposure of SPSmotif. 3) The two Ser residues of
the ERK1/2's NTS are phosphorylated, by an unknown kinase (kinase 1) and probably also by independent, activated ERK1/2. This phosphorylation of the NTS allows the binding of
ERK1/2 to importin7 and transportation of the complex into the nucleus. 4) Importin7 is detached from ERK1/2 by Ran-GTP, followed by its export back to the cytoplasm. The free
ERK1/2 are then able to interact with their nuclear substrates to activate various processes.
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of Ser244 alone had only a minor inﬂuence, but the phosphorylation
of both residues together induced the full rate of translocation upon
stimulation. The KID region was shown to act autonomously in
mediating nuclear translocation of ERK1/2, as well as other pro-
teins. This was shown by ligating the 19 amino acids of ERK1/2's KID to
β-galactodidase-GFP construct (~145 kDa), or to a chimera of 2GFP
(~55 kDa). Only a small portion of this large protein was detected in
the nuclei of transfected cells, which was probably mediated by
endogenous basal phosphorylation, and this shuttle was facilitated by
stimulation. The attachment of non-phosphorylatible 19 amino-acid
stretch prevented the translocation, whereas phosphomimetic
mutants accelerated it without any further effect upon cellular
stimulation. These ﬁndings led to the conclusion that the KID-ERK1/
2 domain is indeed a nuclear translocation signal (NTS), and is likely to
have a general role in the translocation of other proteins as well.
Indeed, we found that the translocated MEK1 and SMAD3, which do
not contain an NLS, do have a similar NTS, and as expected, this
sequence was found to be important for their nuclear translocation.
However, it should be noted that not all translocated proteins contain
this sequence, indicating the existence of additional NTSs.
In order to investigate the involvement of importins in the process
of ERK nuclear translocation, we used Si-RNA of most of these nuclear
shuttlers. We found that only the Si-RNA of importin7 reduced
both non-stimulated and stimulated nuclear translocation of ERK1/2.
Moreover, we found that importin7 directly interacts with ERK1/2, and
this interaction is enhanced upon mitogenic stimulation dependent
on SPS phosphorylation. We also found that ERK1/2 can interact withcertain NUPs, and that this interaction is actually prevented by SPS
phosphorylation. In view of the above, we proposed a model (Fig. 2) in
which cellular stimulation induces ﬁrst the phosphorylation of the
regulatory TEYdomain to allowERK1/2 activation anddetachment from
anchor proteins. The free active ERK1/2 are then phosphorylated on
their SPS domain by several kinases, which may include autopho-
sphorylation by activated ERK1/2. This phosphorylation allows interac-
tion between ERK1/2 and importin7, and this complex then translocates
into the nucleus via the nuclear pores, where the phosphorylation is
important for proper sliding. Importin7 then detaches from ERK1/2
and is exported back to the cytoplasm, while the ERK1/2 themselves
remain free to execute their nuclear functions.
As mentioned above, one of the unique components that
participate in ERK1/2's translocation is importin7, which is a member
of a group of karyopherins that were recently identiﬁed as possible
regulators of shuttling processes [221]. The role of different importins
in the nuclear translocation of NLS-deﬁcient signaling proteins seems
to be very important, but poorly investigated. It has been recently
reported that both TGFβ-induced and basal state import of Smad4
require importins 7 and 8 [222]. Other authors demonstrated that in
digitonin-permeabilized cells, transportin1, importin7, and importin9
promote efﬁcient import of c-Jun into the nucleus [223]. These results
raise the possibility that the role of different importins other than
importin-α/β, is to mediate nuclear translocation of various NLS-
lacking signaling proteins, including the MAPK cascade components.
This may involve a network of signaling protein/importin interactions
that may add yet another facet to the complex mechanisms that
govern nuclear processes, mainly after cellular stimulations.
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The translocation of components of the MAPK cascades into the
nucleus is an important step in the regulation of the large number of
cellular processes governed by these central signaling pathways. The
main components that undergo nuclear translocation are the MAPK,
ERK1/2, JNK, p38 and ERK5, although other components including
MEK1, MEK2, MEK5, MEKK2/3 and several MAPKAPKs were reported
to localize in the nucleus as well. The translocation of the variety of
components into the nucleus plays a role in the regulation of a variety
of nuclear processes that are essential for the induction of many
stimulated cellular functions. The best-studied nuclear process is the
regulation of transcription, which is mainly mediated by the
phosphorylation and activation of many transcription factors. Inter-
estingly, ERK1/2 and ERK5 were reported to bind DNA, and thereby
act as transcriptional repressors or transcription factors of some
genes. In the nucleus, the MAPKs also participate in the regulation of
chromatin remodeling, which is essential for transcription factors'
binding to proper promoters. Finally, MAPKs were reported to
regulate the nuclear localization of regulatory proteins, to induce
nuclear-dependent restriction points of the cell cycle, and tomodulate
the activity of nuclear receptors. These processes cooperate in order to
maintain the delicate regulatory machinery essential for the induction
of most stimulated cellular functions.
Although much information is currently available on the MAPK-
regulated nuclear processes, not much is known on the mechanisms
of nuclear shuttling of the MAPK components. Aside from ERK5, these
components do not contain a canonical NLS, and therefore, their
stimulated nuclear translocation is likely to be regulated by unique
translocation mechanisms. Recently, our group identiﬁed an NTS,
localized in the KID of ERK1/2, and showed that phosphorylation of
two Ser residues in this location is essential for the translocation. We
further demonstrated that this phosphorylation allows the binding of
ERK1/2 with importin7, facilitating the penetration through nuclear
pores and further into the nucleus. This mode of regulation seems to
be common to some other translocating proteins, such as SMAD3 and
MEK1. However, many other proteins that translocate into the
nucleus upon stimulation do not contain the same sequences, and
therefore, are likely to utilize other mechanisms for their transloca-
tion. In this regard, it is likely that other regulatory proteins, including
importin3-13 and RanBPs play an important role in the regulations of
these shuttling processes. The mode of translocation of signaling
proteins after stimulation deserves further investigation, as it may
emerge as an important regulatory step in various cellular processes.
As such, this translocation may serve as a target for therapeutic
intervention in signaling-related diseases, such as cancer, inﬂamma-
tion and diabetes.
Acknowledgements
This work was supported by grants from the Israeli Science
Foundation, and MINERVA. R.S. is an incumbent of the Yale Lewine
and Ella Miller Lewine — professorial chair for cancer research.
References
[1] Y.D. Shaul, R. Seger, The MEK/ERK cascade: from signaling speciﬁcity to diverse
functions, Biochim. Biophys. Acta 1773 (2007) 1213–1226.
[2] M. Raman, W. Chen, M.H. Cobb, Differential regulation and properties of MAPKs,
Oncogene 26 (2007) 3100–3112.
[3] G. Pimienta, J. Pascual, Canonical and alternative MAPK signaling, Cell Cycle 6
(2007) 2628–2632.
[4] P. Coulombe, S. Meloche, Atypical mitogen-activated protein kinases: structure,
regulation and functions, Biochim. Biophys. Acta 1773 (2007) 1376–1387.
[5] S. Yoon, R. Seger, The extracellular signal-regulated kinase: multiple substrates
regulate diverse cellular functions, Growth Factors 24 (2006) 21–44.
[6] A.G. Turjanski, J.P. Vaque, J.S. Gutkind, MAP kinases and the control of nuclear
events, Oncogene 26 (2007) 3240–3253.[7] Z. Yao, R. Seger, The ERK signaling cascade — views from different subcellular
compartments, Biofactors 35 (2009) 407–416.
[8] A.J. Whitmarsh, Regulation of gene transcription by mitogen-activated protein
kinase signaling pathways, Biochim. Biophys. Acta 1773 (2007) 1285–1298.
[9] E. Zehorai, Z. Yao, A. Plotnikov, R. Seger, The subcellular localization of MEK and
ERK-A novel nuclear translocation signal (NTS) paves a way to the nucleus, Mol.
Cell. Endocrinol. 314 (2010) 213–220.
[10] A. Clark, J. Dean, C. Tudor, J. Saklatvala, Post-transcriptional gene regulation by
MAP kinases via AU-rich elements, Front. Biosci. 14 (2009) 847–871.
[11] R. Seger, E.G. Krebs, The MAPK signaling cascade, FASEB J. 9 (1995) 726–735.
[12] T. Niault, M. Baccarini, Targets of Raf in tumorigenesis, Carcinogenesis 7 (2010)
1165–1174.
[13] W. Kolch, G. Heidecker, G. Kochs, R. Hummel, H. Vahidi, H. Mischak, G.
Finkenzeller, D. Marme, U.R. Rapp, Protein kinase C alpha activates RAF-1 by
direct phosphorylation, Nature 364 (1993) 249–252.
[14] D.N. Chadee, J.M. Kyriakis, MLK3 is required for mitogen activation of B-Raf, ERK
and cell proliferation, Nat. Cell Biol. 6 (2004) 770–7768 Epub 2004 Jul 2018.
[15] Y.D. Shaul, G. Gibor, A. Plotnikov, R. Seger, Speciﬁc phosphorylation and
activation of ERK1c by MEK1b: a unique route in the ERK cascade, Genes Dev.
23 (2009) 1779–1790.
[16] R. Seger, Y. Biener, R. Feinstein, T. Hanoch, A. Gazit, Y. Zick, Differential activation
of mitogen-activated protein kinase and S6 kinase signaling pathways by 12-O-
tetradecanoylphorbol-13-acetate (TPA) and insulin. Evidence for involvement of a
TPA-stimulated protein-tyrosine kinase, J. Biol. Chem. 270 (1995) 28325–28330.
[17] Y. Yung, Z. Yao, T. Hanoch, R. Seger, ERK1b, a 46-kDa ERK isoform that is
differentially regulated by MEK, J. Biol. Chem. 275 (2000) 15799–15808.
[18] D.M. Aebersold, Y.D. Shaul, Y. Yung, N. Yarom, Z. Yao, T. Hanoch, R. Seger,
Extracellular signal-regulated kinase 1c (ERK1c), a novel 42-kilodalton ERK,
demonstrates unique modes of regulation, localization, and function, Mol. Cell.
Biol. 24 (2004) 10000–10015.
[19] D.K. Pokholok, J. Zeitlinger, N.M. Hannett, D.B. Reynolds, R.A. Young, Activated
signal transduction kinases frequently occupy target genes, Science 313 (2006)
533–536.
[20] S. Hu, Z. Xie, A. Onishi, X. Yu, L. Jiang, J. Lin, H.S. Rho, C. Woodard, H. Wang, J.S.
Jeong, S. Long, X. He, H. Wade, S. Blackshaw, J. Qian, H. Zhu, Proﬁling the human
protein-DNA interactome reveals ERK2 as a transcriptional repressor of
interferon signaling, Cell 139 (2009) 610–622.
[21] E.K. Kim, E.J. Choi, Pathological roles of MAPK signaling pathways in human
diseases, Biochim. Biophys. Acta 1802 (2010) 396–405.
[22] W.E. Tidyman, K.A. Rauen, The RASopathies: developmental syndromes of
Ras/MAPK pathway dysregulation, Curr. Opin. Genet. Dev. 19 (2009) 230–236.
[23] J.F. Tanti, J. Jager, Cellular mechanisms of insulin resistance: role of stress-
regulated serine kinases and insulin receptor substrates (IRS) serine phosphor-
ylation, Curr. Opin. Pharmacol. 9 (2009) 753–762.
[24] A.S. Dhillon, S. Hagan, O. Rath, W. Kolch, MAP kinase signalling pathways in
cancer, Oncogene 26 (2007) 3279–3290.
[25] C. Montagut, J. Settleman, Targeting the RAF-MEK-ERK pathway in cancer
therapy, Cancer Lett. 283 (2009) 125–134.
[26] R.J. Davis, MAPKs: new JNK expands the group, Trends Biochem. Sci. 19 (1994)
470–473.
[27] G.L. Johnson, K. Nakamura, The c-jun kinase/stress-activated pathway: regula-
tion, function and role in human disease, Biochim. Biophys. Acta 1773 (2007)
1341–1348.
[28] C.R.Weston, R.J. Davis, The JNK signal transduction pathway, Curr. Opin. Cell Biol.
19 (2007) 142–149.
[29] M.A. Bogoyevitch, K.R. Ngoei, T.T. Zhao, Y.Y. Yeap, D.C. Ng, c-Jun N-terminal
kinase (JNK) signaling: recent advances and challenges, Biochim. Biophys. Acta
1804 (2010) 463–475.
[30] J.R. Bradley, J.S. Pober, Tumor necrosis factor receptor-associated factors (TRAFs),
Oncogene 20 (2001) 6482–6491.
[31] I. Dan, N.M. Watanabe, A. Kusumi, The Ste20 group kinases as regulators of MAP
kinase cascades, Trends Cell Biol. 11 (2001) 220–230.
[32] E.A. Craig, M.V. Stevens, R.R. Vaillancourt, T.D. Camenisch, MAP3Ks as central
regulators of cell fate during development, Dev. Dyn. 237 (2008) 3102–3114.
[33] A.J. Whitmarsh, The JIP family of MAPK scaffold proteins, Biochem. Soc. Trans. 34
(2006) 828–832.
[34] X. Wang, A. Destrument, C. Tournier, Physiological roles of MKK4 and MKK7:
insights from animal models, Biochim. Biophys. Acta 1773 (2007) 1349–1357.
[35] W. Bi, L. Xiao, Y. Jia, J. Wu, Q. Xie, J. Ren, G. Ji, Z. Yuan, N-terminal kinase
enhances MST1-mediated pro-apoptotic signaling through phosphorylation at
serine 82, J. Biol. Chem. 285 (2010) 6259–6264.
[36] S. Ludwig, K. Engel, A. Hoffmeyer, G. Sithanandam, B. Neufeld, D. Palm, M.
Gaestel, U.R. Rapp, 3pK, a novel mitogen-activated protein (MAP) kinase-
activated protein kinase, is targeted by three MAP kinase pathways, Mol. Cell.
Biol. 16 (1996) 6687–6697.
[37] D.N. Dhanasekaran, E.P. Reddy, JNK signaling in apoptosis, Oncogene 27 (2008)
6245–6251.
[38] M. Rincon, R.J. Davis, Regulation of the immune response by stress-activated
protein kinases, Immunol. Rev. 228 (2009) 212–224.
[39] W. Haeusgen, R. Boehm, Y. Zhao, T. Herdegen, V. Waetzig, Speciﬁc activities of
individual c-Jun N-terminal kinases in the brain, Neuroscience 161 (2009)
951–959.
[40] A. Gdalyahu, I. Ghosh, T. Levy, T. Sapir, S. Sapoznik, Y. Fishler, D. Azoulai, O.
Reiner, DCX, a new mediator of the JNK pathway, EMBO J. 23 (2004) 823–832.
[41] K. Zhang, R.J. Kaufman, From endoplasmic-reticulum stress to the inﬂammatory
response, Nature 454 (2008) 455–462.
1630 A. Plotnikov et al. / Biochimica et Biophysica Acta 1813 (2011) 1619–1633[42] E.F. Wagner, A.R. Nebreda, Signal integration by JNK and p38 MAPK pathways in
cancer development, Nat. Rev. Cancer 9 (2009) 537–549.
[43] J.M. Kyriakis, J. Avruch, Mammalian mitogen-activated protein kinase signal
transduction pathways activated by stress and inﬂammation, Physiol. Rev. 81
(2001) 807–869.
[44] T. Zarubin, J. Han, Activation and signaling of the p38 MAP kinase pathway, Cell
Res. 15 (2005) 11–18.
[45] L.R. Coulthard, D.E. White, D.L. Jones, M.F. McDermott, S.A. Burchill, p38(MAPK):
stress responses from molecular mechanisms to therapeutics, Trends Mol. Med.
15 (2009) 369–379.
[46] D.K. Morrison, R.J. Davis, Regulation of MAP kinase signaling modules by scaffold
proteins in mammals, Annu. Rev. Cell Dev. Biol. 19 (2003) 91–118.
[47] B.D. Cuevas, A.N. Abell, G.L. Johnson, Role of mitogen-activated protein kinase
kinase kinases in signal integration, Oncogene 26 (2007) 3159–3171.
[48] H. Rubinfeld, R. Seger, The ERK cascade: a prototype of MAPK signaling,
Mol. Biotechnol. 31 (2005) 151–174.
[49] A.J. Whitmarsh, R.J. Davis, Role of mitogen-activated protein kinase kinase 4 in
cancer, Oncogene 26 (2007) 3172–3184.
[50] B. Ge, H. Gram, F. Di Padova, B. Huang, L. New, R.J. Ulevitch, Y. Luo, J. Han,
MAPKK-independent activation of p38alpha mediated by TAB1-dependent
autophosphorylation of p38alpha, Science 295 (2002) 1291–1294.
[51] J.M. Salvador, P.R. Mittelstadt, T. Guszczynski, T.D. Copeland, H. Yamaguchi, E.
Appella, A.J. Fornace Jr., J.D. Ashwell, Alternative p38 activation pathwaymediated
by T cell receptor-proximal tyrosine kinases, Nat. Immunol. 6 (2005) 390–395.
[52] J.J. Gills, S.S. Castillo, C. Zhang, P.A. Petukhov, R.M. Memmott, M. Hollingshead, N.
Warfel, J. Han, A.P. Kozikowski, P.A. Dennis, Phosphatidylinositol ether lipid
analogues that inhibit AKT also independently activate the stress kinase,
p38alpha, through MKK3/6-independent and -dependent mechanisms, J. Biol.
Chem. 282 (2007) 27020–27029.
[53] A. Shiryaev, U. Moens, Mitogen-activated protein kinase p38 and MK2, MK3 and
MK5: menage a trois or menage a quatre? Cell. Signal. 22 (2010) 1185–1192.
[54] M. Buxade, J.L. Parra-Palau, C.G. Proud, The Mnks: MAP kinase-interacting kinases
(MAP kinase signal-integrating kinases), Front. Biosci. 13 (2008) 5359–5373.
[55] L. Vermeulen, W.V. Berghe, I.M. Beck, K. De Bosscher, G. Haegeman, The versatile
role ofMSKs in transcriptional regulation, Trends Biochem. Sci. 34 (2009) 311–318.
[56] G. Huang, L.Z. Shi, H. Chi, Regulation of JNK and p38 MAPK in the immune
system: signal integration, propagation and termination, Cytokine 48 (2009)
161–169.
[57] S.J. Sohn, J. Thompson, A. Winoto, Apoptosis during negative selection of
autoreactive thymocytes, Curr. Opin. Immunol. 19 (2007) 510–515.
[58] J. Maruyama, I. Naguro, K. Takeda, H. Ichijo, Stress-activated MAP kinase
cascades in cellular senescence, Curr. Med. Chem. 16 (2009) 1229–1235.
[59] T.M. Thornton, M. Rincon, Non-classical p38 map kinase functions: cell cycle
checkpoints and survival, Int. J. Biol. Sci. 5 (2009) 44–51.
[60] A. Cuenda, S. Rousseau, p38 MAP-kinases pathway regulation, function and role
in human diseases, Biochim. Biophys. Acta 1773 (2007) 1358–1375.
[61] G.L. Schieven, The p38alpha kinase plays a central role in inﬂammation, Curr.
Top. Med. Chem. 9 (2009) 1038–1048.
[62] Z. Liu, W. Cao, p38 mitogen-activated protein kinase: a critical node linking
insulin resistance and cardiovascular diseases in type 2 diabetes mellitus,
Endocr. Metab. Immune Disord. Drug Targets 9 (2009) 38–46.
[63] M. Loesch, G. Chen, The p38 MAPK stress pathway as a tumor suppressor or
more? Front. Biosci. 13 (2008) 3581–3593.
[64] J. Moscat, M.T. Diaz-Meco, A. Albert, S. Campuzano, Cell signaling and function
organized by PB1 domain interactions, Mol. Cell 23 (2006) 631–640.
[65] S. Nishimoto, E. Nishida, MAPK signalling: ERK5 versus ERK1/2, EMBO Rep. 7
(2006) 782–786.
[66] X. Wang, C. Tournier, Regulation of cellular functions by the ERK5 signalling
pathway, Cell. Signal. 18 (2006) 753–760.
[67] W. Sun, K. Kesavan, B.C. Schaefer, T.P. Garrington, M. Ware, N.L. Johnson, E.W.
Gelfand, G.L. Johnson, MEKK2 associates with the adapter protein Lad/RIBP and
regulates the MEK5-BMK1/ERK5 pathway, J. Biol. Chem. 276 (2001) 5093–5100.
[68] B.E. Xu, S. Stippec, L. Lenertz, B.H. Lee, W. Zhang, Y.K. Lee, M.H. Cobb, WNK1
activates ERK5 by an MEKK2/3-dependent mechanism, J. Biol. Chem. 279 (2004)
7826–7831.
[69] T.H. Chao, M. Hayashi, R.I. Tapping, Y. Kato, J.D. Lee, MEKK3 directly regulates
MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1)
signaling pathway, J. Biol. Chem. 274 (1999) 36035–36038.
[70] M. Chiariello, M.J. Marinissen, J.S. Gutkind, Multiple mitogen-activated protein
kinase signaling pathways connect the cot oncoprotein to the c-jun promoter
and to cellular transformation, Mol. Cell. Biol. 20 (2000) 1747–1758.
[71] M. Hayashi, R.I. Tapping, T.H. Chao, J.F. Lo, C.C. King, Y. Yang, J.D. Lee, BMK1
mediates growth factor-induced cell proliferation through direct cellular
activation of serum and glucocorticoid-inducible kinase, J. Biol. Chem. 276
(2001) 8631–8634.
[72] H.G. Kasler, J. Victoria, O. Duramad, A. Winoto, ERK5 is a novel type of mitogen-
activated protein kinase containing a transcriptional activation domain, Mol.
Cell. Biol. 20 (2000) 8382–8389.
[73] O.L. Roberts, K. Holmes, J. Muller, D.A. Cross, M.J. Cross, ERK5 and the regulation
of endothelial cell function, Biochem. Soc. Trans. 37 (2009) 1254–1259.
[74] S.J. Sohn, G.M. Lewis, A. Winoto, Non-redundant function of the MEK5-ERK5
pathway in thymocyte apoptosis, EMBO J. 27 (2008) 1896–1906.
[75] C. Yan, M. Takahashi, M. Okuda, J.D. Lee, B.C. Berk, Fluid shear stress stimulates
big mitogen-activated protein kinase 1 (BMK1) activity in endothelial cells.
Dependence on tyrosine kinases and intracellular calcium, J. Biol. Chem. 274
(1999) 143–150.[76] J. Whyte, O. Bergin, A. Bianchi, S. McNally, F. Martin, Key signalling nodes in
mammary gland development and cancer. Mitogen-activated protein kinase
signalling in experimental models of breast cancer progression and in mammary
gland development, Breast Cancer Res. 11 (2009) 209.
[77] Q. Yang, X. Deng, B. Lu, M. Cameron, C. Fearns, M.P. Patricelli, J.R. Yates 3rd, N.S.
Gray, J.D. Lee, Pharmacological inhibition of BMK1 suppresses tumor growth
through promyelocytic leukemia protein, Cancer Cell 18 (2010) 258–267.
[78] A. Brunet, D. Roux, P. Lenormand, S. Dowd, S. Keyse, J. Pouyssegur, Nuclear
translocation of p42/p44 mitogen-activated protein kinase is required for
growth factor-induced gene expression and cell cycle entry, EMBO J. 18 (1999)
664–674.
[79] E. Formstecher, J.W. Ramos, M. Fauquet, D.A. Calderwood, J.C. Hsieh, B. Canton, X.T.
Nguyen, J.V. Barnier, J. Camonis, M.H. Ginsberg, H. Chneiweiss, PEA-15
mediates cytoplasmic sequestration of ERK MAP kinase, Dev. Cell 1 (2001)
239–250.
[80] M. Tresini, A. Lorenzini, C. Torres, V.J. Cristofalo, Modulation of replicative
senescence of diploid human cells by nuclear ERK signaling, J. Biol. Chem. 282
(2007) 4136–4151.
[81] B. Bjorkblom, J.C. Vainio, V. Hongisto, T. Herdegen, M.J. Courtney, E.T. Coffey, All
JNKs can kill, but nuclear localization is critical for neuronal death, J. Biol. Chem.
283 (2008) 19704–19713.
[82] C.A. Hazzalin, E. Cano, A. Cuenda, M.J. Barratt, P. Cohen, L.C. Mahadevan, p38/RK
is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2
phosphorylation are insufﬁcient, Curr. Biol. 6 (1996) 1028–1031.
[83] H. Daub, J.V. Olsen, M. Bairlein, F. Gnad, F.S. Oppermann, R. Korner, Z. Greff, G.
Keri, O. Stemmann, M. Mann, Kinase-selective enrichment enables quantitative
phosphoproteomics of the kinome across the cell cycle, Mol. Cell 31 (2008)
438–448.
[84] B. Casar, A. Pinto, P. Crespo, ERK dimers and scaffold proteins: unexpected
partners for a forgotten (cytoplasmic) task, Cell Cycle 8 (2009) 1007–1013.
[85] S. Galli, O. Jahn, R. Hitt, D. Hesse, L. Opitz, U. Plessmann, H. Urlaub, J.J. Poderoso,
E.A. Jares-Erijman, T.M. Jovin, A new paradigm for MAPK: structural
interactions of hERK1 with mitochondria in HeLa cells, PLoS ONE 4 (2009)
e7541.
[86] S. Torii, M. Kusakabe, T. Yamamoto, M. Maekawa, E. Nishida, Sef is a spatial
regulator for Ras/MAP kinase signaling, Dev. Cell 7 (2004) 33–44.
[87] D. Teis, N. Taub, R. Kurzbauer, D. Hilber, M.E. de Araujo, M. Erlacher, M.
Offterdinger, A. Villunger, S. Geley, G. Bohn, C. Klein, M.W. Hess, L.A. Huber, p14-
MP1-MEK1 signaling regulates endosomal trafﬁc and cellular proliferation
during tissue homeostasis, J. Cell Biol. 175 (2006) 861–868.
[88] N. Fehrenbacher, D. Bar-Sagi, M. Philips, Ras/MAPK signaling from endomem-
branes, Mol. Oncol. 3 (2009) 297–307.
[89] H. Gille, A.D. Sharrocks, P.E. Shaw, Phosphorylation of transcription factor
p62TCF by MAP kinase stimulates ternary complex formation at c-fos promoter,
Nature 358 (1992) 414–417.
[90] R. Marais, J. Wynne, R. Treisman, The SRF accessory protein Elk-1 contains a
growth factor-regulated transcriptional activation domain, Cell 73 (1993)
381–393.
[91] R. Treisman, Regulation of transcription by MAP kinase cascades, Curr. Opin. Cell
Biol. 8 (1996) 205–215.
[92] G. Buchwalter, C. Gross, B. Wasylyk, Ets ternary complex transcription factors,
Gene 324 (2004) 1–14.
[93] F.H. Cruzalegui, E. Cano, R. Treisman, ERK activation induces phosphorylation
of Elk-1 at multiple S/T-P motifs to high stoichiometry, Oncogene 18 (1999)
7948–7957.
[94] A.D. Sharrocks, S.H. Yang, A. Galanis, Docking domains and substrate-speciﬁcity
determination for MAP kinases, Trends Biochem. Sci. 25 (2000) 448–453.
[95] D. Jacobs, D. Glossip, H. Xing, A.J. Muslin, K. Kornfeld, Multiple docking sites on
substrate proteins form a modular system that mediates recognition by ERK
MAP kinase, Genes Dev. 13 (1999) 163–175.
[96] R. Eferl, E.F. Wagner, AP-1: a double-edged sword in tumorigenesis, Nat. Rev.
Cancer 3 (2003) 859–868.
[97] L.O. Murphy, S. Smith, R.H. Chen, D.C. Fingar, J. Blenis, Molecular interpretation of
ERK signal duration by immediate early gene products, Nat. Cell Biol. 4 (2002)
556–564.
[98] C.J. Marshall, Speciﬁcity of receptor tyrosine kinase signaling: transient versus
sustained extracellular signal-regulated kinase activation, Cell 80 (1995)
179–185.
[99] L.O. Murphy, J.P. MacKeigan, J. Blenis, A network of immediate early gene
products propagates subtle differences in mitogen-activated protein kinase
signal amplitude and duration, Mol. Cell. Biol. 24 (2004) 144–153.
[100] G. Mavrothalassitis, J. Ghysdael, Proteins of the ETS family with transcriptional
repressor activity, Oncogene 19 (2000) 6524–6532.
[101] M. Fornerod, M. Ohno, M. Yoshida, I.W. Mattaj, CRM1 is an export receptor for
leucine-rich nuclear export signals, Cell 90 (1997) 1051–1060.
[102] K. Stade, C.S. Ford, C. Guthrie, K. Weis, Exportin 1 (Crm1p) is an essential nuclear
export factor, Cell 90 (1997) 1041–1050.
[103] D.N. Sgouras, M.A. Athanasiou, G.J. Beal Jr., R.J. Fisher, D.G. Blair, G.J.
Mavrothalassitis, ERF: an ETS domain protein with strong transcriptional
repressor activity, can suppress ETS-associated tumorigenesis and is regulated
by phosphorylation during cell cycle and mitogenic stimulation, EMBO J. 14
(1995) 4781–4793.
[104] S. Polychronopoulos, M. Verykokakis, M.N. Yazicioglu, M. Sakarellos-Daitsiotis,
M.H. Cobb, G. Mavrothalassitis, The transcriptional ETS2 repressor factor
associates with active and inactive Erks through distinct FXF motifs, J. Biol.
Chem. 281 (2006) 25601–25611.
1631A. Plotnikov et al. / Biochimica et Biophysica Acta 1813 (2011) 1619–1633[105] L. Le Gallic, L. Virgilio, P. Cohen, B. Biteau, G. Mavrothalassitis, ERF nuclear
shuttling, a continuous monitor of Erk activity that links it to cell cycle
progression, Mol. Cell. Biol. 24 (2004) 1206–1218.
[106] K. Brami-Cherrier, E. Roze, J.A. Girault, S. Betuing, J. Caboche, Role of the ERK/
MSK1 signalling pathway in chromatin remodelling and brain responses to
drugs of abuse, J. Neurochem. 108 (2009) 1323–1335.
[107] S.P. Zhong, W.Y. Ma, Z. Dong, ERKs and p38 kinases mediate ultraviolet B-
induced phosphorylation of histone H3 at serine 10, J. Biol. Chem. 275 (2000)
20980–20984.
[108] P.S. Rao, A. Satelli, S. Zhang, S.K. Srivastava, K.S. Srivenugopal, U.S. Rao, RNF2 is
the target for phosphorylation by the p38 MAPK and ERK signaling pathways,
Proteomics 9 (2009) 2776–2787.
[109] X. Zhou, V. Richon, A. Wang, X. Yang, R. Rifkind, P. Marks, Histone deacetylase 4
associates with extracellular signal-regulated, Proc. Natl Acad. Sci. USA 97
(2000) 14329–14333.
[110] A. Soloaga, S. Thomson, G.R. Wiggin, N. Rampersaud, M.H. Dyson, C.A. Hazzalin,
L.C. Mahadevan, J.S. Arthur, MSK2 and MSK1 mediate the mitogen- and stress-
induced phosphorylation of histone H3 and HMG-14, EMBO J. 22 (2003)
2788–2797.
[111] M. Cohen-Armon, L. Visochek, D. Rozensal, A. Kalal, I. Geistrikh, R. Klein, S.
Bendetz-Nezer, Z. Yao, R. Seger, DNA-independent PARP-1 activation by
phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation,
Mol. Cell 25 (2007) 297–308.
[112] P.S. Shapiro, A.M. Whalen, N.S. Tolwinski, J. Wilsbacher, S.J. Froelich-Ammon, M.
Garcia, N. Osheroff, N.G. Ahn, Extracellular signal-regulated kinase activates
topoisomerase IIalpha through a mechanism independent of phosphorylation,
Mol. Cell. Biol. 19 (1999) 3551–3560.
[113] E.A. Nigg, Nucleocytoplasmic transport: signals, mechanisms and regulation,
Nature 386 (1997) 779–787.
[114] M. Suntharalingam, S.R. Wente, Peering through the pore: nuclear pore complex
structure, assembly, and function, Dev. Cell 4 (2003) 775–789.
[115] L.J. Terry, S.R. Wente, Flexible gates: dynamic topologies and functions for FG
nucleoporins in nucleocytoplasmic transport, Eukaryot. Cell 8 (2009) 1814–1827.
[116] M. Capelson, M.W. Hetzer, The role of nuclear pores in gene regulation,
development and disease, EMBO Rep. 10 (2009) 697–705.
[117] Y. Matsubayashi, M. Fukuda, E. Nishida, Evidence for existence of a nuclear
pore complex-mediated, cytosol-independent pathway of nuclear transloca-
tion of ERK MAP kinase in permeabilized cells, J. Biol. Chem. 276 (2001)
41755–41760.
[118] A.W. Whitehurst, J.L. Wilsbacher, Y. You, K. Luby-Phelps, M.S. Moore, M.H. Cobb,
ERK2 enters the nucleus by a carrier-independent mechanism, Proc. Natl Acad.
Sci. USA 99 (2002) 7496–7501.
[119] T. Lee, A.N. Hoofnagle, Y. Kabuyama, J. Stroud, X. Min, E.J. Goldsmith, L. Chen, K.A.
Resing, N.G. Ahn, Docking motif interactions in MAP kinases revealed by
hydrogen exchange mass spectrometry, Mol. Cell 14 (2004) 43–55.
[120] D. Chuderland, A. Konson, R. Seger, Identiﬁcation and characterization of a
general nuclear translocation signal in signaling proteins, Mol. Cell 31 (2008)
850–861.
[121] S.T. Eblen, N.V. Kumar, K. Shah, M.J. Henderson, C.K. Watts, K.M. Shokat, M.J.
Weber, Identiﬁcation of novel ERK2 substrates through use of an engineered
kinase and ATP analogs, J. Biol. Chem. 278 (2003) 14926–14935.
[122] T. Vomastek, M.P. Iwanicki, W.R. Burack, D. Tiwari, D. Kumar, J.T. Parsons, M.J.
Weber, V.K. Nandicoori, Extracellular signal-regulated kinase 2 (ERK2)
phosphorylation sites and docking domain on the nuclear pore complex protein
Tpr cooperatively regulate ERK2-Tpr interaction, Mol. Cell. Biol. 28 (2008)
6954–6966.
[123] R.S. Faustino, T.G. Maddaford, G.N. Pierce, Mitogen activated protein kinase at
the nuclear pore complex, J. Cell. Mol. Med. 15 (4) (2010) 928–937.
[124] H. Kosako, N. Yamaguchi, C. Aranami, M. Ushiyama, S. Kose, N. Imamoto, H.
Taniguchi, E. Nishida, S. Hattori, Phosphoproteomics reveals new ERK MAP
kinase targets and links ERK to nucleoporin-mediated nuclear transport, Nat.
Struct. Mol. Biol. 16 (2009) 1026–1035.
[125] S.O. Yoon, S. Shin, Y. Liu, B.A. Ballif, M.S. Woo, S.P. Gygi, J. Blenis, Ran-binding
protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocy-
toplasmic transport, Mol. Cell 29 (2008) 362–375.
[126] S. Kuersten, M. Ohno, I.W. Mattaj, Nucleocytoplasmic transport: Ran, beta and
beyond, Trends Cell Biol. 11 (2001) 497–503.
[127] I.G. Macara, Transport into and out of the nucleus, Microbiol. Mol. Biol. Rev. 65
(2001) 570–5948 table of contents.
[128] S. Bendetz-Nezer, R. Seger, Full molecular page of MEK1, AfCS/Nature Signaling
Gateway (2005), doi:10.1038/mp.a001505.01.
[129] S. Bendetz-Nezer, R. Seger, Full molecular page of MEK2, AfCS/Nature Signaling
Gateway (2005), doi:10.1038/mp.a001506.01.
[130] P. Lenormand, C. Sardet, G. Pages, G. L'Allemain, A. Brunet, J. Pouyssegur, Growth
factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk)
but not of their activator MAP kinase kinase (p45mapkk) in ﬁbroblasts, J. Cell
Biol. 122 (1993) 1079–1088.
[131] C.F. Zheng, K.L. Guan, Cytoplasmic localization of the mitogen-activated protein
kinase activator MEK, J. Biol. Chem. 269 (1994) 19947–19952.
[132] S. Stewart, M. Sundaram, Y. Zhang, J. Lee, M. Han, K.L. Guan, Kinase suppressor of
Ras forms a multiprotein signaling complex and modulates MEK localization,
Mol. Cell. Biol. 19 (1999) 5523–5534.
[133] M. Fukuda, I. Gotoh, Y. Gotoh, E. Nishida, Cytoplasmic localization of mitogen-
activated protein kinase kinase directed by its NH2-terminal, leucine-rich short
amino acid sequence, which acts as a nuclear export signal, J. Biol. Chem. 271
(1996) 20024–20028.[134] M. Fukuda, I. Gotoh, M. Adachi, Y. Gotoh, E. Nishida, A novel regulatory
mechanism in themitogen-activated protein (MAP) kinase cascade. Role nuclear
export signal MAP kinase kinase, J. Biol. Chem. 272 (1997) 32642–32648.
[135] H. Rubinfeld, T. Hanoch, R. Seger, Identiﬁcation of a cytoplasmic-retention
sequence in ERK2, J. Biol. Chem. 274 (1999) 30349–30352.
[136] H. Jaaro, H. Rubinfeld, T. Hanoch, R. Seger, Nuclear translocation of mitogen-
activated protein kinase kinase (MEK1) in response to mitogenic stimulation,
Proc. Natl Acad. Sci. USA 94 (1997) 3742–3747.
[137] N.S. Tolwinski, P.S. Shapiro, S. Goueli, N.G. Ahn, Nuclear localization of mitogen-
activated protein kinase kinase 1 (MKK1) is promoted by serum stimulation and
G2-M progression. Requirement phosphorylation activation lip signaling
downstream MKK, J. Biol. Chem. 274 (1999) 6168–6174.
[138] Z. Yao, I. Flash, Z. Raviv, Y. Yung, Y. Asscher, S. Pleban, R. Seger, Non-regulated
and stimulated mechanisms cooperate in the nuclear accumulation of MEK1,
Oncogene 20 (2001) 7588–7596.
[139] M. Adachi, M. Fukuda, E. Nishida, Nuclear export of MAP kinase (ERK) involves a
MAP kinase kinase (MEK)-dependent active transport mechanism, J. Cell Biol.
148 (2000) 849–856.
[140] E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, R. Seger,
Interaction with MEK causes nuclear export and downregulation of peroxi-
some proliferator-activated receptor gamma, Mol. Cell. Biol. 27 (2007)
803–817.
[141] R.L. Perry, M.H. Parker, M.A. Rudnicki, Activated MEK1 binds the nuclear MyoD
transcriptional complex to repress transactivation, Mol. Cell 8 (2001)
291–301.
[142] S.H. Yang, A.J. Whitmarsh, R.J. Davis, A.D. Sharrocks, Differential targeting of MAP
kinases to the ETS-domain transcription factor Elk-1, EMBO J. 17 (1998)
1740–1749.
[143] S. Kamakura, T. Moriguchi, E. Nishida, Activation of the protein kinase ERK5/
BMK1 by receptor tyrosine kinases. Identiﬁcation and characterization of a
signaling pathway to the nucleus, J. Biol. Chem. 274 (1999) 26563–26571.
[144] S. Morton, R.J. Davis, A. McLaren, P. Cohen, A reinvestigation of the multisite
phosphorylation of the transcription factor c-Jun, EMBO J. 22 (2003)
3876–3886.
[145] E. Alvarez, I.C. Northwood, F.A. Gonzalez, D.A. Latour, A. Seth, C. Abate, T. Curran,
R.J. Davis, Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate
protein phosphorylation. Characterization of the phosphorylation of c-myc and
c-jun proteins by an epidermal growth factor receptor threonine 669 protein
kinase, J. Biol. Chem. 266 (1991) 15277–15285.
[146] D. Edbauer, D. Cheng, M.N. Batterton, C.F. Wang, D.M. Duong, M.B. Yaffe, J. Peng,
M. Sheng, Identiﬁcation and characterization of neuronal mitogen-activated
protein kinase substrates using a speciﬁc phosphomotif antibody, Mol. Cell.
Proteomics 8 (2009) 681–695.
[147] D. Stokoe, B. Caudwell, P.T. Cohen, P. Cohen, The substrate speciﬁcity and
structure of mitogen-activated protein (MAP) kinase-activated protein kinase-2,
Biochem. J. 296 (Pt 3) (1993) 843–849.
[148] A. Donella-Deana, A. Lavoinne, O. Marin, L.A. Pinna, P. Cohen, An analysis of the
substrate speciﬁcity of insulin-stimulated protein kinase-1, a mammalian
homologue of S6 kinase-II, Biochim. Biophys. Acta 1178 (1993) 189–193.
[149] B. Drobic, B. Perez-Cadahia, J. Yu, S.K. Kung, J.R. Davie, Promoter chromatin
remodeling of immediate-early genes is mediated through H3 phosphorylation
at either serine 28 or 10 by the MSK1 multi-protein complex, Nucleic Acids Res.
38 (2010) 3196–3208.
[150] S.Y. Fuchs, V.A. Fried, Z. Ronai, Stress-activated kinases regulate protein stability,
Oncogene 17 (1998) 1483–1490.
[151] I.A. Manke, A. Nguyen, D. Lim, M.Q. Stewart, A.E. Elia, M.B. Yaffe, MAPKAP kinase-
2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase
progression in response to UV irradiation, Mol. Cell 17 (2005) 37–48.
[152] M.A. Bogoyevitch, B. Kobe, Uses for JNK: the many and varied substrates of the
c-Jun N-terminal kinases, Microbiol. Mol. Biol. Rev. 70 (2006) 1061–1095.
[153] M. Hibi, A. Lin, T. Smeal, A. Minden, M. Karin, Identiﬁcation of an oncoprotein-
and UV-responsive protein kinase that binds and potentiates the c-Jun activation
domain, Genes Dev. 7 (1993) 2135–2148.
[154] E. Shaulian, AP-1 — The Jun proteins: oncogenes or tumor suppressors in
disguise? Cell. Signal. 22 (2010) 894–899.
[155] B. Derijard, M. Hibi, I.H. Wu, T. Barrett, B. Su, T. Deng, M. Karin, R.J. Davis, JNK1: a
protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates
the c-Jun activation domain, Cell 76 (1994) 1025–1027.
[156] E. Shaulian, M. Karin, AP-1 as a regulator of cell life and death, Nat. Cell Biol. 4
(2002) E131–E136.
[157] A.M. Musti, M. Treier, D. Bohmann, Reduced ubiquitin-dependent degradation of
c-Jun after phosphorylation by MAP kinases, Science 275 (1997) 400–402.
[158] D. Barsyte-Lovejoy, A. Galanis, A.D. Sharrocks, Speciﬁcity determinants in MAPK
signaling to transcription factors, J. Biol. Chem. 277 (2002) 9896–9903.
[159] D. Barsyte-Lovejoy, A. Galanis, A. Clancy, A.D. Sharrocks, ERK5 is targeted to
myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif, Biochem.
J. 381 (2004) 693–699.
[160] D. Chuderland, R. Seger, Protein–protein interactions in the regulation of the
extracellular signal-regulated kinase, Mol. Biotechnol. 29 (2005) 57–74.
[161] A.J. Bardwell, E. Frankson, L. Bardwell, Selectivity of docking sites in MAPK
kinases, J. Biol. Chem. 284 (2009) 13165–13173.
[162] D.M. Cox, M. Du, M. Marback, E.C. Yang, J. Chan, K.W. Siu, J.C. McDermott,
Phosphorylation motifs regulating the stability and function of myocyte
enhancer factor 2A, J. Biol. Chem. 278 (2003) 15297–15303.
[163] E. Appella, C.W. Anderson, Post-translational modiﬁcations and activation of p53
by genotoxic stresses, Eur. J. Biochem. 268 (2001) 2764–2772.
1632 A. Plotnikov et al. / Biochimica et Biophysica Acta 1813 (2011) 1619–1633[164] M. Oren, A. Damalas, T. Gottlieb, D. Michael, J. Taplick, J.F. Leal, R. Maya, M. Moas,
R. Seger, Y. Taya, A. Ben-Ze'ev, Regulation of p53: intricate loops and delicate
balances, Biochem. Pharmacol. 64 (2002) 865–871.
[165] D.M. Milne, L.E. Campbell, D.G. Campbell, D.W. Meek, p53 is phosphorylated in
vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic
of the c-Jun kinase, JNK1, J. Biol. Chem. 270 (1995) 5511–5518.
[166] T. Lin, N.K. Mak, M.S. Yang, MAPK regulate p53-dependent cell death induced
by benzo[a]pyrene: involvement of p53 phosphorylation and acetylation,
Toxicology 247 (2008) 145–153.
[167] D.M. Milne, D.G. Campbell, F.B. Caudwell, D.W. Meek, Phosphorylation of the
tumor suppressor protein p53 by mitogen-activated protein kinases, J. Biol.
Chem. 269 (1994) 9253–9260.
[168] N.V. Oleinik, N.I. Krupenko, S.A. Krupenko, Cooperation between JNK1 and JNK2
in activation of p53 apoptotic pathway, Oncogene 26 (2007) 7222–7230.
[169] T.S. Eisinger-Mathason, J. Andrade, D.A. Lannigan, RSK in tumorigenesis:
connections to steroid signaling, Steroids 75 (2010) 191–202.
[170] E. Burgermeister, R. Seger, MAPK kinases as nucleo-cytoplasmic shuttles for
PPARgamma, Cell Cycle 6 (2007) 1539–1548.
[171] P.M. Barger, A.C. Browning, A.N. Garner, D.P. Kelly, p38 mitogen-activated
protein kinase activates peroxisome proliferator-activated receptor alpha: a
potential role in the cardiac metabolic stress response, J. Biol. Chem. 276 (2001)
44495–44501.
[172] M.J. Yoon, G.Y. Lee, J.J. Chung, Y.H. Ahn, S.H. Hong, J.B. Kim, Adiponectin
increases fatty acid oxidation in skeletal muscle cells by sequential activation
of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and
peroxisome proliferator-activated receptor alpha, Diabetes 55 (2006)
2562–2570.
[173] M. Gianni, A. Bauer, E. Garattini, P. Chambon, C. Rochette-Egly, Phosphorylation
by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma
degradation and transactivation, EMBO J. 21 (2002) 3760–3769.
[174] Z. Chai, L. Yang, B. Yu, Q. He, W.I. Li, R. Zhou, T. Zhang, X. Zheng, J. Xie, p38
mitogen-activated protein kinase-dependent regulation of SRC-3 and involve-
ment in retinoic acid receptor alpha signaling in embryonic cortical neurons,
IUBMB Life 61 (2009) 670–678.
[175] D.E. Frigo, A. Basu, E.N. Nierth-Simpson, C.B. Weldon, C.M. Dugan, S. Elliott, B.M.
Collins-Burow, V.A. Salvo, Y. Zhu, L.I. Melnik, G.N. Lopez, P.J. Kushner, T.J. Curiel,
B.G. Rowan, J.A. McLachlan, M.E. Burow, p38 mitogen-activated protein kinase
stimulates estrogen-mediated transcription and proliferation through the
phosphorylation and potentiation of the p160 coactivator glucocorticoid
receptor-interacting protein 1, Mol. Endocrinol. 20 (2006) 971–983.
[176] D. Gioeli, B.E. Black, V. Gordon, A. Spencer, C.T. Kesler, S.T. Eblen, B.M. Paschal, M.
J. Weber, Stress kinase signaling regulates androgen receptor phosphorylation,
transcription, and localization, Mol. Endocrinol. 20 (2006) 503–515.
[177] M. Itoh, M. Adachi, H. Yasui, M. Takekawa, H. Tanaka, K. Imai, Nuclear export of
glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated
phosphorylation, Mol. Endocrinol. 16 (2002) 2382–2392.
[178] H.S. Camp, S.R. Tafuri, T. Leff, c-Jun N-terminal kinase phosphorylates
peroxisome proliferator-activated receptor-gamma1 and negatively regulates
its transcriptional activity, Endocrinology 140 (1999) 392–397.
[179] K.K. Mann, A.M. Padovani, Q. Guo, A.L. Colosimo, H.Y. Lee, J.M. Kurie, W.H. Miller
Jr., Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated
RXRalpha phosphorylation, J. Clin. Invest. 115 (2005) 2924–2933.
[180] H. Srinivas, D.M. Juroske, S. Kalyankrishna, D.D. Cody, R.E. Price, X.C. Xu, R.
Narayanan, N.L. Weigel, J.M. Kurie, c-Jun N-terminal kinase contributes to
aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing
proteasomal degradation of retinoic acid receptor alpha, Mol. Cell. Biol. 25
(2005) 1054–1069.
[181] Y. Mebratu, Y. Tesfaigzi, How ERK1/2 activation controls cell proliferation
and cell death is subcellular localization the answer? Cell Cycle 8 (2009)
1168–1175.
[182] P. Gomez del Arco, S. Martinez-Martinez, J.L. Maldonado, I. Ortega-Perez, J.M.
Redondo, A role for the p38 MAP kinase pathway in the nuclear shuttling of
NFATp, J. Biol. Chem. 275 (2000) 13872–13878.
[183] T.T. Yang, R.Y. Yu, A. Agadir, G.J. Gao, R. Campos-Gonzalez, C. Tournier, C.W.
Chow, Integration of protein kinases mTOR and extracellular signal-regulated
kinase 5 in regulating nucleocytoplasmic localization of NFATc4, Mol. Cell. Biol.
28 (2008) 3489–3501.
[184] S. Clavel, S. Siffroi-Fernandez, A.S. Coldefy, K. Boulukos, D.F. Pisani, B. Derijard,
Regulation of the intracellular localization of Foxo3a by stress-activated protein
kinase signaling pathways in skeletal muscle cells, Mol. Cell. Biol. 30 (2010)
470–480.
[185] G. Liao, Q. Tao, M. Kofron, J.S. Chen, A. Schloemer, R.J. Davis, J.C. Hsieh, C. Wylie, J.
Heasman, C.Y. Kuan, Jun NH2-terminal kinase (JNK) prevents nuclear beta-
catenin accumulation and regulates axis formation in Xenopus embryos, Proc.
Natl Acad. Sci. USA 103 (2006) 16313–16318.
[186] C.G. Besirli, E.F. Wagner, E.M. Johnson Jr., The limited role of NH2-terminal c-Jun
phosphorylation in neuronal apoptosis: identiﬁcation of the nuclear pore
complex as a potential target of the JNK pathway, J. Cell Biol. 170 (2005)
401–411.
[187] M.N. Richard, J.F. Deniset, A.L. Kneesh, D. Blackwood, G.N. Pierce, Mechanical
stretching stimulates smooth muscle cell growth, nuclear protein import, and
nuclear pore expression through mitogen-activated protein kinase activation, J.
Biol. Chem. 282 (2007) 23081–23088.
[188] J.B. Kelley, B.M. Paschal, Hyperosmotic stress signaling to the nucleus disrupts
the Ran gradient and the production of RanGTP, Mol. Biol. Cell 18 (2007)
4365–4376.[189] H. Morimoto, K. Kondoh, S. Nishimoto, K. Terasawa, E. Nishida, Activation of a
C-terminal transcriptional activation domain of ERK5 by autophosphorylation,
J. Biol. Chem. (2007).
[190] Z. Raviv, E. Kalie, R. Seger, MEK5 and ERK5 are localized in the nuclei of resting as
well as stimulated cells, while MEKK2 translocates from the cytosol to the
nucleus upon stimulation, J. Cell Sci. 117 (2004) 1773–1784.
[191] Z. Yao, S. Yoon, E. Kalie, Z. Raviv, R. Seger, Calcium regulation of EGF-induced
ERK5 activation: role of Lad1-MEKK2 interaction, PLoS ONE 5 (2010).
[192] M. Buschbeck, A. Ullrich, The unique C-terminal tail of the mitogen-activated
protein kinase ERK5 regulates its activation and nuclear shuttling, J. Biol. Chem.
280 (2005) 2659–2667.
[193] K. Kondoh, K. Terasawa, H. Morimoto, E. Nishida, Regulation of nuclear
translocation of extracellular signal-regulated kinase 5 by active nuclear import
and export mechanisms, Mol. Cell. Biol. 26 (2006) 1679–1690.
[194] A.V. Sorokin, E.R. Kim, L.P. Ovchinnikov, Nucleocytoplasmic transport of proteins,
Biochemistry (Mosc) 72 (2007) 1439–1457.
[195] D. Kalderon, B.L. Roberts, W.D. Richardson, A.E. Smith, A short amino acid
sequence able to specify nuclear location, Cell 39 (1984) 499–509.
[196] C. Dingwall, J. Robbins, S.M. Dilworth, B. Roberts, W.D. Richardson, The
nucleoplasmin nuclear location sequence is larger and more complex than
that of SV-40 large T antigen, J. Cell Biol. 107 (1988) 841–849.
[197] D. Christophe, C. Christophe-Hobertus, B. Pichon, Nuclear targeting of proteins:
how many different signals? Cell. Signal. 12 (2000) 337–341.
[198] E.J. Tran, S.R. Wente, Dynamic nuclear pore complexes: life on the edge, Cell 125
(2006) 1041–1053.
[199] B. Sun, M. Karin, NF-kappaB signaling, liver disease and hepatoprotective agents,
Oncogene 27 (2008) 6228–6244.
[200] J.G. Turner, D.M. Sullivan, CRM1-mediated nuclear export of proteins and drug
resistance in cancer, Curr. Med. Chem. 15 (2008) 2648–2655.
[201] P. Sassone-Corsi, Coupling gene expression to cAMP signalling: role of CREB and
CREM, Int. J. Biochem. Cell Biol. 30 (1998) 27–38.
[202] A.T. Harootunian, S.R. Adams, W. Wen, J.L. Meinkoth, S.S. Taylor, R.Y. Tsien,
Movement of the free catalytic subunit of cAMP-dependent protein kinase into
and out of the nucleus can be explained by diffusion, Mol. Biol. Cell 4 (1993)
993–1002.
[203] J.E.J. Darnell, I.M. Kerr, G.R. Stark, Jak-STAT pathways and transcriptional
activation in response to IFNs and other extracellular signaling proteins, Science
264 (1994) 1415–1421.
[204] K. Melen, L. Kinnunen, I. Julkunen, Arginine/lysine-rich structural element is
involved in interferon-induced nuclear import of STATs, J. Biol. Chem. 276
(2001) 16447–16455.
[205] T. Kawashima, Y.C. Bao, Y. Nomura, Y. Moon, Y. Tonozuka, Y. Minoshima, T.
Hatori, A. Tsuchiya, M. Kiyono, T. Nosaka, H. Nakajima, D.A. Williams, T.
Kitamura, Rac1 and a GTPase-activating protein. MgcRacGAP are required
nuclear translocation STAT transcription factors, J. Cell Biol. 175 (2006) 937–946.
[206] C.C. Williams, J.G. Allison, G.A. Vidal, M.E. Burow, B.S. Beckman, L. Marrero, F.E.
Jones, The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by
functioning as a STAT5A nuclear chaperone, J. Cell Biol. 167 (2004) 469–478.
[207] L. Xu, C. Alarcon, S. Col, J. Massague, Distinct domain utilization by Smad3 and
Smad4 for nucleoporin interaction and nuclear import, J. Biol. Chem. 13 (2003) 13.
[208] F. Fagotto, U. Gluck, B.M. Gumbiner, Nuclear localization signal-independent and
importin/karyopherin-independent nuclear import of beta-catenin, Curr. Biol.
8 (1998) 181–190.
[209] L. Xu, J. Massague, Nucleocytoplasmic shuttling of signal transducers, Nat. Rev.
Mol. Cell Biol. 5 (2004) 209–219.
[210] A.A. Reszka, R. Seger, C.D. Diltz, E.G. Krebs, E.H. Fischer, Association of mitogen-
activated protein kinase with the microtubule cytoskeleton, Proc. Natl Acad. Sci.
USA 92 (1995) 8881–8885.
[211] A. Zuniga, J. Torres, J. Ubeda, R. Pulido, Interaction of mitogen-activated protein
kinases with the kinase interaction motif of the tyrosine phosphatase PTP-SL
provides substrate speciﬁcity and retains ERK2 in the cytoplasm, J. Biol. Chem.
274 (1999) 21900–21907.
[212] I. Wolf, H. Rubinfeld, S. Yoon, G. Marmor, T. Hanoch, R. Seger, Involvement of the
activation loop of ERK in the detachment from cytosolic anchoring, J. Biol. Chem.
276 (2001) 24490–24497.
[213] M. Adachi, M. Fukuda, E. Nishida, Two co-existing mechanisms for nuclear
import of MAP kinase: passive diffusion of a monomer and active transport of a
dimer, EMBO J. 18 (1999) 5347–5358.
[214] A.V. Khokhlatchev, B. Canagarajah, J. Wilsbacher, M. Robinson, M. Atkinson, E.
Goldsmith, M.H. Cobb, Phosphorylation of the MAP kinase ERK2 promotes its
homodimerization and nuclear translocation, Cell 93 (1998) 605–615.
[215] D.S. Lidke, F. Huang, J.N. Post, B. Rieger, J. Wilsbacher, J.L. Thomas, J. Pouyssegur,
T.M. Jovin, P. Lenormand, ERK nuclear translocation is dimerization-independent
but controlled by the rate of phosphorylation, J. Biol. Chem. 285 (2010)
3092–3102.
[216] B. Casar, A. Pinto, P. Crespo, Essential role of ERK dimers in the activation of
cytoplasmic but not nuclear substrates by ERK-scaffold complexes, Mol. Cell 31
(2008) 708–721.
[217] J.A. Lorenzen, S.E. Baker, F. Denhez, M.B. Melnick, D.L. Brower, L.A. Perkins,
Nuclear import of activated D-ERK by DIM-7, an importin family member
encoded by the gene moleskin, Development 128 (2001) 1403–1414.
[218] D. Chuderland, R. Seger, Calcium regulates ERK signaling by modulating its
protein–protein interactions, Commun. Integr. Biol. 1 (2008) 4–5.
[219] A. Ranganathan, M.N. Yazicioglu, M.H. Cobb, The nuclear localization of ERK2
occurs by mechanisms both independent of and dependent on energy, J. Biol.
Chem. 281 (2006) 15645–15652.
1633A. Plotnikov et al. / Biochimica et Biophysica Acta 1813 (2011) 1619–1633[220] M.N. Yazicioglu, D.L. Goad, A. Ranganathan, A.W. Whitehurst, E.J. Goldsmith,
M.H. Cobb, Mutations in ERK2 binding sites affect nuclear entry, J. Biol. Chem.
282 (2007) 28759–28767.
[221] K.M. Wagstaff, D.A. Jans, Importins and beyond: non-conventional nuclear
transport mechanisms, Trafﬁc 10 (2009) 1188–1198.[222] X. Yao, X. Chen, C. Cottonham, L. Xu, Preferential utilization of Imp7/8 in nuclear
import of Smads, J. Biol. Chem. 283 (2008) 22867–22874.
[223] I. Waldmann, S. Walde, R.H. Kehlenbach, Nuclear import of c-Jun is
mediated by multiple transport receptors, J. Biol. Chem. 282 (2007)
27685–27692.
